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Summary 
Introduction 
Resistin is an adipokine, originally identified in adipose tissue and its plasma levels are 
elevated in obesity. Resistin induces insulin resistance and affects energy homeostasis by 
reducing food intake. Plasma levels of resistin are correlated with the development and 
severity of heart failure, hypertension and myocardial infarction, suggesting that resistin has 
cardiovascular effects, however, the mechanisms underlying such effects are unclear. 
Characteristics of obesity include impaired metabolic regulation and cardiovascular 
dysfunction such as increased sympathetic nerve activity to the kidney and skeletal muscle 
vasculature. It is unknown whether resistin affects sympathetic nerve activity. 
 
This thesis investigates (1) the effect of centrally administered resistin on (i) blood pressure 
and heart rate, (ii) sympathetic nerve activity targeting the kidney and skeletal muscle 
vasculature, (iii) sympathetic nerve activity to brown adipose tissue and thermogenesis and 
(2) (i) the intracellular signalling pathways mediating the changes in sympathetic nerve 
activity affecting the kidney and brown adipose tissue by resistin and (ii) the role of 
Extracellular regulated kinase-1/2  in the brain in mediating the effects of resistin on brown 
adipose tissue temperature, body core temperature and protein markers of thermogenesis in 
brown adipose tissue (uncoupling protein-1 and peroxisome proliferator-activated receptor 
gamma coactivator 1-α). 
 
Methods 
Overnight-fasted Sprague-Dawley rats were anesthetized (induced with isoflurane gas 2.5%-
3% in O2, and maintained with intravenous urethane, 1–1.4 g/kg initially, followed by 
supplemental doses of 0.05 g/kg as required). Resistin (7ug) or vehicle was administered into 
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the lateral cerebral ventricle. In separate groups of animals, blood pressure, heart rate, 
lumbar sympathetic nerve activity, renal sympathetic nerve activity, brown adipose tissue 
sympathetic nerve activity, brown adipose tissue temperature and body core temperature 
were recorded before and after the drug administration. To identify the intracellular 
signalling pathways mediating the effects of resistin on sympathetic nerve activity, resistin 
was administered in the presence of either the Extracellular Regulated Kinase-1/2 inhibitor 
(U0126, 7µg) or Phosphatidylinositol-3-kinase inhibitor (LY294002, 5µg) and the response 
on sympathetic nerve activity to the kidney or brown adipose tissue was measured in 
different groups of animals. In some experiments the potential central sites of action of 
resistin were investigated. In those experiments, brains were removed for 
immunohistochemical processing to detect the protein Fos, a marker of increased neuronal 
activation. In other experiments, brown adipose tissue was removed and mRNA was 
extracted to investigate the role of resistin on genetic markers of thermogenesis in brown 
adipose tissue. The role of Extracellular regulated kinase-1/2 in the brain in mediating the 
effects of resistin on thermogenesis in brown adipose tissue was also investigated. 
 
Results 
In chapter 3, intracerebroventricular resistin was found to produce long lasting significant 
increases in lumbar and renal sympathetic nerve activity by approximately 40% (p<0.05), 
however, it did not induce a significant change in blood pressure and heart rate. Central 
administration of resistin significantly increased Fos production in paraventricular nucleus, 
supraoptic nucleus and subfornical organ (p<0.05) but not in the arcuate nucleus. The 
findings suggest that resistin increases the sympathetic nerve activity to the kidneys and 
skeletal muscle vasculature, however, it may not be sufficient to increase the blood pressure. 
Investigating the sites of action of resistin in the brain suggests that the paraventricular 
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nucleus may be a key brain area mediating the effects of resistin on sympathetic nerve 
activity.  
 
In chapter four, the increase in renal sympathetic nerve activity by intracerebroventricular 
resistin was found to be mediated by Phosphatidylinositol-3-kinase in the brain, since 
inhibition of Phosphatidylinositol-3-kinase by pre-treatment with LY294002 (5µg), 
significantly prevented the action of resistin on renal sympathetic nerve activity (p<0.05, 
compared to control). Inhibition of Extracellular regulated kinase-1/2 had no effect on the 
renal sympathetic nerve activity response to resistin. 
 
In chapter 5, intracerebroventricular resistin was shown to significantly reduce brown 
adipose tissue sympathetic nerve activity by over 50% (p<0.05), brown adipose tissue 
temperature (1.27 + 0.46 ºC) and body core temperature (1.32 + 0.49 ºC). The data suggests 
that resistin reduces thermogenesis in brown adipose tissue. Furthermore, resistin does not 
have a generalised effect on sympathetic nerve activity since resistin increased lumbar and 
renal sympathetic nerve activity but reduced brown adipose tissue sympathetic nerve 
activity. 
 
In chapter 6, the reduction in brown adipose tissue sympathetic nerve activity by resistin was 
found to be mediated by Extracellular regulated kinase-1/2 in the brain, since pre-treatment 
with U0126 (7µg), prevented the action of resistin on brown adipose tissue sympathetic 
nerve activity for approximately 2 hours. Inhibition of Phosphatidylinositol-3-kinase had no 
effect on the response induced by resistin on brown adipose tissue sympathetic nerve 
activity. Extracellular regulated kinase-1/2 inhibition in the brain, attenuated the effects of 
resistin on brown adipose tissue temperature (p<0.05) and body core temperature. 
Intracerebroventricular resistin reduced the gene expression of uncoupling protein-1, a 
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marker of thermogenesis in brown adipose tissue and this effect was attenuated by inhibition 
of Extracellular regulated kinase-1/2, although the effects were not statistically significant. 
Resistin had no effect on peroxisome proliferator-activated receptor gamma coactivator 1-α, 
a transcription factor involved in thermogenesis. 
 
Summary and conclusion 
The results show that intracerebroventricular resistin increases sympathetic nerve activity to 
the kidney and skeletal muscle vasculature. Elevated sympathetic nerve activity to these 
cardiovascular organs is observed in obesity, a condition in which resistin levels are 
increased. Resistin did not significantly change the blood pressure or heart rate, suggesting 
that increases in sympathetic nerve activity by resistin may not be generalised. This is 
supported by my finding that intracerebroventricular resistin reduced sympathetic nerve 
activity to brown adipose tissue. This was accompanied by reduction in brown adipose tissue 
temperature and body core temperature. The results suggest that resistin increases the 
sympathetic nerve activity to cardiovascular organs such as kidney and skeletal muscle 
vasculature, but reduces sympathetic nerve activity to metabolically active organs like brown 
adipose tissue. Investigating the intracellular signalling pathways mediating the effects of 
resistin showed that Phosphatidylinositol-3-kinase mediated the effects of resistin on renal 
sympathetic nerve activity and Extracellular regulated kinase-1/2 mediated the effects of 
resistin on brown adipose tissue sympathetic nerve activity. 
 
The findings indicate that resistin has differential effects on sympathetic nerve activity to 
tissues involved in metabolic and cardiovascular regulation. The increased lumbar and renal 
sympathetic nerve activity and the decreased thermogenesis in brown adipose tissue elicited 
by resistin suggest that it may contribute to the sympathetic nerve over-activity to 
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cardiovascular organs and reduced energy expenditure observed in obesity and metabolic 
syndrome. 
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CHAPTER 1: Introduction 
1.1 Introduction 
Obesity is a major social problem, expanding rapidly from western societies to the rest of the 
world. The growing health concern about obesity for both developed and developing 
countries has prompted the World Health Organisation to declare obesity as a global 
epidemic. About 60% of the Australian adult population is either overweight or obese (1). 
The prevalence of excess weight in children and adolescents is approximately 25%, and it is 
estimated that within 30 years approximately 60% of children will be overweight. Obesity is 
a well-characterized independent risk factor for cardiovascular disease and high blood 
pressure (2). 
 
The sympathetic nervous system plays a major role in homeostasis. The level of activity in 
sympathetic nerves innervating blood vessels and the kidneys is a major determinant of 
blood pressure. Increased sympathetic nerve activity to the blood vessels and kidneys are 
characteristic of obesity and metabolic syndrome (3, 4). In obesity, body mass index is 
independently correlated with sympathetic nerve activation, suggesting sympatho-
stimulating effects are related to visceral adiposity (4). 
 
Adipose tissue is not only a storage site for fat but is known to act as a major endocrine 
organ that synthesises and releases a variety of different hormones including leptin, 
adiponectin, and resistin, collectively known as adipokines. Leptin is the most intensively 
studied adipokine. Plasma levels of leptin are increased in obesity and it acts centrally to 
increase sympathetic nerve activity (SNA) to the skeletal muscle vasculature and kidneys (5-
7). 
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Adiponectin is the only other adipokine that has been studied in relation to effects on 
sympathetic nerve function. Adiponectin reduces sympathetic nerve activity, thus opposing 
the actions of leptin. Adiponectin levels are decreased in obesity and its levels are negatively 
correlated to hypertension in obesity whilst leptin levels are positively correlated. The 
findings highlight the important role of adipokines on SNA regulating cardiovascular and 
metabolic functions. With the exception of leptin and adiponectin, however, little is known 
about the effects of other adipose-derived hormones, for example resistin. 
 
Resistin is a newly discovered adipokine, originally identified in adipose tissue (8), but now 
known to be expressed in smaller amounts in a variety of tissues including the hypothalamus 
(9, 10). It belongs to a family of cysteine-rich proteins capable of inducing insulin resistance.  
The plasma levels of resistin are reported to be increased with obesity and type 2 diabetes (8, 
11-16), and together with its influence on insulin sensitivity, it has been suggested that 
resistin may be a link between type 2 diabetes and obesity (8).  Resistin also has a role in the 
regulation of metabolism by decreasing food intake, and its expression is influenced by 
dietary intake, such that the level of resistin in plasma is increased by feeding and reduced 
by fasting (8).  
 
Several epidemiological studies have shown that resistin is associated with cardiovascular 
disease for example plasma resistin levels were reported to be correlated with the 
development and severity of heart failure, ischemic heart disease, hypertension and vascular 
disease (14, 17-25), however, its influence on SNA had not been investigated prior to my 
work. 
 
This thesis investigates the role of resistin on SNA to cardiovascular tissues and metabolic 
organs. In this first chapter, I provide a description of resistin and its distribution, and 
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discuss its cardiovascular and metabolic actions and highlight the gaps in the knowledge 
about cardiovascular and metabolic functions of resistin. 
 
1.2 Resistin and its structure 
Resistin is a member of the resistin-like molecule (RELM) hormone family. Two other 
members of the RELM family include RELM-alpha and RELM-beta. All RELM family 
members are characterized by ten conserved cysteine residues. Resistin and RELM-beta 
contain an additional cysteine near their amino termini, which is conserved among species 
(26). The rsesistin gene is located on chromosome 19 in humans and on chromosome 8 in 
mice (8, 27). The mouse resistin genomic sequence displays 46% sequence identity with the 
human resistin sequence (27). Human and mouse resistin show 64% sequence identity at the 
mRNA level while the two proteins exhibit 59% identity at the amino acid levels (8, 27). 
Resistin is secreted as a disulphide-linked homotrimer (8) and circulates in plasma as either a 
trimer or a hexamer (28). Human resistin has 108 amino acids while in rodents, resistin has 
114 amino acids. 
 
The receptor for resistin has not been clearly identified to date, however, several studies have 
investigated the potential receptors for resistin in rodents and humans. It has been suggested 
that Delta Decorin, which is a cleavage product of decorin lacking the glycation site, may 
serve as a functional receptor for resistin in adipocyte progenitor cells in mice (29).  
 
In 3T3-L1 cells, tyrosine kinase-like orphan receptor-1 was found to be inhibited by resistin, 
resulting in modulating glucose uptake and promoting adipogenesis (30). A recent study in 
2013 by Benomar et al (31), identified Toll-like receptor-4 as a binding site for resistin in the 
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hypothalamus in rats. In human cells, Toll-like receptor-4 may serve as a receptor for the 
pro-inflammatory effects of resistin (32).  
 
1.3 Tissue distribution of resistin 
Resistin is found in number of different tissues in the periphery and in the brain. 
 
1.3.1 Peripheral distribution of resistin 
 
The plasma levels of resistin are reported to be about 7.3-14.3 ng/ml in humans (15) and 
35.7-42.9 ng/ml in rats (33). In rodents, white adipose tissue is the main source of resistin. 
Resistin mRNA expression has been shown in white adipose tissue of mice (8) and rats (34). 
In mice, resistin mRNA levels vary as a function of the white adipose depot and gender, with 
the highest level of expression in female gonadal fat. Immunohistochemistry of epididymal 
white adipose tissue showed that the resistin protein was abundant in adipocyte cytoplasm 
(8). 
In contrast to rodents, the expression level of resistin mRNA in human adipocytes is low and 
is about 1/250 of that in the mouse (10). Resistin in humans is mainly produced by 
macrophages (10). In obesity, macrophages that infiltrated into visceral white adipose tissue 
are the predominant source of resistin (35).  
 
Resistin has also been detected in a variety of other tissues in the periphery including adrenal 
glands (36, 37), gastrointestinal tract (37), liver (38), human pancreatic islets (39), pituitary 
gland (9), skeletal muscle (37), bone marrow, breast, colon, heart, kidney, lung, liver, 
prostate, spleen, testis, thymus, thyroid, uterus (36) and synovial fluid of patients with 
rheumatoid arthritis and osteoarthritis (40). Resistin mRNA expression was found in human 
placenta where it is localised to trophoblastic cells, suggesting the possibility of a role for 
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resistin in modulating insulin sensitivity during pregnancy (41, 42). Finally resistin has been 
identified in brown adipose tissue (BAT) in rat (37), however, the role of resistin in BAT 
physiology is not clearly understood. 
 
1.3.2 Central distribution of resistin 
Resistin mRNA has been detected in hypothalamus in rodents (43) and in humans it has been 
found in the whole brain (36) and cerebrospinal fluid (44). 
Hypothalamus 
By using in situ hybridization, Tovar et al (43) detected mouse resistin mRNA expression in 
the arcuate nucleus, ventromedial nucleus and hippocampus. 
They showed that following the intracerebroventricular (ICV) administration of resistin (10 
micrograms) in rats, the only hypothalamic region to show resistin-induced Fos protein 
expression was the arcuate nucleus of fasted but not fed rats. This observation suggests that 
the hypothalamus may be more responsive to resistin in the fasted state.  
Cerebrospinal fluid 
Resistin was detected in human cerebrospinal fluid (CSF) by Kos et al (44), however, in that 
study, the raised circulating resistin levels did not correspond to higher CSF levels, 
suggesting limited uptake into the CSF, possibly by an active transport mechanism across 
the blood brain barrier. This, of course, does not exclude local production of resistin in the 
brain. 
 
1.4 Resistin in obesity and type 2 diabetes 
Resistin levels are elevated in obesity and diabetes (8, 11). An increase in serum resistin 
levels can increase blood glucose levels by inducing insulin resistance (45). For example in 
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rodents, over-expression of resistin or administration of exogenous resistin decreased insulin 
sensitivity and altered glucose metabolism. Blocking resistin activity by neutralising 
antibodies improved insulin sensitivity and restored glucose homeostasis (46). Furthermore, 
resistin-knockout mice have lower fasting blood glucose levels and enhanced glucose 
tolerance and insulin sensitivity (47). There are several studies in humans indicating a 
positive correlation between resistin levels and increased obesity, visceral (16, 48, 49) and 
abdominal fat (50), body mass index, fasting blood glucose (14, 15) and insulin resistance 
(51). 
 
Although the majority of studies confirm the correlation between resistin levels and obesity 
and type 2 diabetes, a few authors have reported that resistin was not increased in patients 
with severe insulin resistance and type 2 diabetes (15, 52). These contrasting findings may 
be due to differences in ethnic backgrounds, average body mass index and gender of the 
participants. Thus the metabolic role of resistin in humans remains controversial not only 
due to these studies but also due to the fact that resistin in humans is mainly produced by 
macrophages that have infiltrated into the adipose tissue while in rodents it is produced by 
adipocytes.  
 
The recent report from Lazar’s lab (53) suggests a physiological role of resistin in glucose 
homeostasis. They created a transgenic mouse model that lacks mouse resistin but produces 
human resistin. When those mice were placed on a high-fat diet, there was an increase in 
human resistin production which induced insulin resistance. This result was similar to the 
reports from wild-type mice in which adipocyte-derived mouse induced insulin resistance. 
The findings provide strong evidence that although the site of resistin production differs 
between species, resistin is physiologically important in glucose homeostasis. 
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1.5 Cardiovascular disease in obesity 
Obesity is an independent well-characterized cardiovascular risk factor. It is also linked to 
cardiovascular disease through diabetes, hypertension, dyslipidemia and vascular disease (2, 
54, 55). Overweight or obesity is a major social problem. The growing public health concern 
surrounding obesity and subsequent cardiovascular or metabolic disease have focused 
attention on treatment and prevention of these conditions. Thus, understanding the 
mechanisms underlying obesity, and linking obesity with cardiovascular or metabolic 
disease, is crucial for designing therapeutic strategies to target obesity and its cardiovascular 
and metabolic complications.  
 
 
1.6 Excessive sympathetic activation in obesity and metabolic syndrome 
In obesity and metabolic syndrome, there is an increase in sympathetic nerve activity to the 
skeletal muscle blood vessels and to the kidneys (3, 4), (56). For example many studies 
indicate that obese humans have about 50-100% higher levels of muscle sympathetic nerve 
activity compared with their non-obese peers (56). 
 
In obesity, body mass index is independently correlated with renal norepinephrine spillover 
rate (57) and sympathetic nerve activation (4). Interestingly, weight loss is associated with a 
reduction in muscle sympathetic nerve activity (58) and whole body norepinephrine spillover 
(59). More detailed study on fat composition showed that abdominal visceral fat plays an 
important role in the link between obesity and sympathetic overactivity since muscle 
sympathetic nerve activity has been reported to be about 40% higher in men with higher 
abdominal visceral fat compared with subjects with lower abdominal visceral fat but with the 
same total fat mass (60). The sympathetic nervous system plays an essential role in the 
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regulation of metabolic and cardiovascular functions. Sympathetic over-activity is 
characteristic of a number of cardiovascular disorders such as hypertension and heart failure 
(4, 61). 
 
1.6.1 Role of adipocytokines in sympathetic overactivity 
Studies have revealed that adipose tissue in addition to storing fat also produces and secretes 
different hormones. Some of these hormones have been implicated in cardiovascular 
pathophysiology such as leptin, adiponectin and resistin (2). Studies on two adipocyte-
derived hormones, leptin and adiponectin, have revealed a role for them in regulating 
sympathetic nerve activity (6, 62-65). Resistin, a recently discovered adipocytokine elicits 
many metabolic effects that are similar to leptin. For example leptin and resistin levels are 
increased in obesity and correlate with the severity of cardiovascular disease in humans (Fig 
1.1). It is unknown however, whether resistin has any direct effect on regulating sympathetic 
nerve activity. This is an important question because any effect of resistin on sympathetic 
nerve activity may contribute to the altered cardiovascular function in obesity. 
 
1.6.2 Leptin 
Leptin is the most well-known adipocytokine. It was discovered by Friedman in 1994 (66). 
Leptin levels are increased in obesity in proportion to fat mass and leptin is well known to 
act in the central nervous system to reduce food intake and increase energy expenditure by 
regulating neuropeptides in the hypothalamus such as neuropeptide-Y & agouti-related 
protein and stimulating proopiomelanocortin neurons in the arcuate nucleus of the 
hypothalamus (67). 
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Clinical studies have revealed that leptin is an independent risk factor for coronary heart 
disease. It induces platelet aggregation and promotes arterial thrombosis, inflammation and 
contributes to cardiovascular disease such as hypertension (68). Leptin is known to increase 
sympathetic nerve activity to the kidney, adrenal gland and skeletal muscle vasculature (5, 
69) (Fig 1.2). This increased sympathetic nerve activity is now believed to be an important 
contributor to obesity induced hypertension in which the sympathetic nerve activity and 
arterial blood pressure are both increased (70, 71).  
 
Leptin also increases sympathetic nerve activity to the BAT suggesting an important 
physiological role of leptin in the regulation of thermogenesis (62) (Fig 1.2). In rodents, 
brown adipose tissue is the primary thermogenic organ which has a significant role in 
regulating thermogenesis and energy expenditure (72).  
1.6.3 Adiponectin 
Adiponectin levels in plasma are decreased in obesity and it is the only other adipocytokine 
known to influence SNA (73). Adiponectin suppresses renal SNA and reduces blood 
pressure while increasing sympathetic outflow to brown adipose tissue (64, 65) (Fig 1.2). 
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Figure 1.1 The adipokine resistin is released from adipose tissue. Effects of resistin on 
sympathetic nerve activity (SNA) to kidney, skeletal muscle vasculature and brown adipose 
tissue are not known. 
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Figure 1.2  
The adipokines leptin and adiponectin are released from adipose tissue. Left Panel: Leptin 
acts centrally to increase sympathetic nerve activity (SNA) to blood vessels, kidney and 
brown adipose tissue. Right Panel: Adiponectin reduces SNA to the kidneys and skeletal 
muscle blood vessels but increases SNA to brown adipose tissue.  
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1.7 Cardiovascular impact of resistin 
1.7.1 Hypertension 
Several studies have shown that plasma resistin levels are associated with either the presence 
or the development of high blood pressure in humans. A positive association between 
plasma resistin levels and hypertension, measured using 24 hours ambulatory blood pressure 
monitoring, has been observed (21, 24). In adults with hypertension, higher circulating 
plasma resistin levels were associated with a lower estimated glomerular filtration rate and 
higher albuminuria. This association highlights the possible contribution of resistin to the 
progression of chronic renal disease in hypertensive patients (74-76). 
 
It is of great interest that increased plasma resistin levels has been observed in a young 
healthy population with a positive family history for essential hypertension (77). Findings 
from this study as well as a study on the population of women without previous history of 
hypertension or diabetes, suggested that plasma resistin levels may have a predictive value 
since plasma resistin levels were associated with the risk of developing hypertension over 
the 14 years of follow up (78).  
 
Although the majority of studies have shown a correlation between plasma resistin levels 
and hypertension, the contribution of resistin to hypertension remains to be clarified as there 
are some studies that have not observed a significant correlation (79, 80) or found a 
correlation only in patients with other risk factors present such as type 2 diabetes (81). 
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1.7.2 Heart function 
Resistin is expressed in the heart and increased expression has been found in diabetic hearts 
(82). This can be clinically important since resistin has been shown to reduce insulin 
stimulated glucose uptake in cardiomyocytes (83). This action can impair cardiac function 
and contribute to the incidence of cardiomyopathy in diabetic patients (84).  
 
Resistin may also influence the function of the heart by reducing contractility, increasing 
apoptosis and fibrosis in the heart (82, 85). Increased fibrosis and hypertrophy are 
characteristics of cardiomyopathy. Resistin can also induce cardiac hypertrophy (82) and 
recently this has been shown to involve reduced activity of AMP-activated protein kinase 
and increased activity of mammalian target of rapamycin (86). These findings together with 
the observations that resistin increased pro-fibrotic mediators such as fibronectin and 
collagen 1 and 2 (85), reinforces the potential role of resistin in diabetic cardiomyopathy.  
 
Plasma resistin levels are elevated following myocardial infarction (87). Of greater interest, 
are reports that plasma resistin levels are correlated with the incidence of myocardial 
infarction (but not ischemic stroke) in a large study of 26490 people (88) suggesting that 
plasma resistin levels may be predictive of myocardial infarction. More recent studies also 
confirm an association between plasma resistin levels and ischemic heart disease (18) and 
incidence of atrial fibrillation (89). 
 
Given that myocardial infarction is a major cause of heart failure, one would expect that 
plasma resistin levels should correlate to heart failure. In two clinical studies of over 2000 
participants each, the plasma resistin levels have indeed been correlated to the incidence of 
heart failure; Butler et al (19) followed elderly patients with an average age of 74 years for 
about 9.4 years, whilst Frankel et al (20) followed patients who were younger (average age 
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of 60 years) for approximately 6 years. These studies strongly suggested that plasma resistin 
concentrations are predictive of new incidence of heart failure, independent of other 
cardiovascular risk factors. More recent studies have also confirmed an association between 
plasma resistin levels and ischemic heart disease (18), incidence of atrial fibrillation (89) and 
progression of chronic heart failure (17). 
 
1.7.3 Atherosclerosis and Inflammation 
Inflammation in obesity 
As obesity develops, there is a progressive infiltration of macrophages into the adipose 
tissue. The infiltration of macrophage causes changes in adipocyte size and function. For 
example, in obesity, adipocytes begin to secrete low levels of tumor necrosis factor-alpha 
(TNF-α) which contributes further to this inflammation. Increased secretion of leptin in 
combination with decreased production of adiponectin by adipocytes may also contribute to 
macrophage accumulation by stimulating the transport of macrophages into the adipose 
tissue and promoting adhesion of macrophages to endothelial cells resulting in chronic 
peripheral inflammation (90). This chronic peripheral inflammation observed in obesity is 
also accompanied by inflammation in the brain. The adipokine leptin has been shown to 
contribute to central inflammation by stimulating the release of interlukin-1β (IL-1β) from 
microglial cells in the brain (91). 
 
Since resistin in humans is primarily produced by macrophages (10, 92, 93), many studies 
have confirmed the strong  correlation of serum resistin levels with circulating inflammatory 
markers including TNF-α, IL-6 and C-reactive protein (CRP). (13, 14, 94-96). This 
correlation becomes important because CRP levels are associated with high blood pressure 
(94) and atherosclerotic cardiovascular disease in humans (97). Resistin also stimulates the 
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secretion of inflammatory cytokines such as TNF-α, IL-12, IL-8, IL6 and monocyte 
chemoattractant protein-1 (MCP-1) (98). 
 
White adipose tissue inflammation 
In 2009, using a mouse model of human hyper-resistinaemia, Qantani et al (53) 
demonstrated that with a high fat diet, there is an increase in human resistin expression in 
WAT and macrophage infiltration into the WAT, which is augmented by a resistin-
dependent increase in the MCP-1 leading to further inflammation, muscle lipid accumulation 
and insulin resistance. This effect of macrophage-derived human resistin in WAT 
contributes to promoting and maintaining an inflammatory environment such as that 
observed in metabolic syndrome in humans. 
 
Vascular inflammation and atherosclerosis  
Plasma resistin levels have been correlated with markers of inflammation, including C-
reactive protein, TNF-α and IL6 in plasma (99), and it is well known that inflammatory 
cytokines are key mediators in atherosclerotic plaque formation (100). Resistin has been 
found in atherosclerotic plaques in mice and humans, and is produced by macrophages that 
have infiltrated the vessel wall (101). Additionally, resistin mRNA levels in atherosclerotic 
lesions progressively increase during the development of atherosclerosis (51). This suggests 
that resistin may have a role in atherosclerosis and in the cardiovascular sequelae, and this is 
supported by various clinical studies. In a cross-sectional study on asymptomatic subjects 
with a family history of premature coronary artery disease, plasma resistin levels correlated 
with coronary artery calcification, a quantitative index of atherosclerosis (99). Patients 
diagnosed with premature coronary artery disease were also found to have higher serum 
levels of resistin (102).  In patients with multi-vessel coronary artery disease, elevated 
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plasma resistin was a strong, independent predictive factor of major adverse cardiac events 
(103).  
 
The mechanisms by which resistin influences atherosclerotic plaque formation are under 
intense investigation at present. Evidence suggests that resistin increases adhesion 
molecules, chemo-attractant proteins and smooth muscle cell proliferation (101, 104-106). 
Resistin increases both the expression of intracellular adhesion molecule-1 (ICAM-1) and 
vascular cellular adhesion molecule 1 (VCAM-1) by endothelial cells (101, 104, 105, 107), 
increases VLA-4 (very late antigent-4) on monocytes, increases migration of monocytes and 
enhances the attractant effects of MCP-1 (101). Together, these contribute to monocyte-
endothelial cell adhesion and the resultant infiltration into- and retention of monocytes 
within the blood vessel wall. Recently, it was found that the effects of resistin on ICAM-1 
VCAM-1 are mediated by p38MAPK-dependent pathways (105). Resistin has also been 
reported to increase lipid uptake into macrophages suggesting it can facilitate the 
macrophage to foam cell changes that occur in atherosclerotic plaques (108). Resistin has 
also been reported to alter endothelial function and increase the production of reactive 
oxygen species which could further contribute to vascular inflammation, atherosclerosis and 
the cardiovascular sequelae (109).  
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1.8 Metabolic actions of resistin  
1.8.1 Insulin resistance and glucose homeostasis  
Resistin reduces insulin sensitivity by attenuating insulin receptor phosphorylation, insulin 
receptor substrate 1 phosphorylation, phosphatidylinositol-3-kinase (PI 3-Kinase) activation, 
phosphatidylinositol triphosphate production, and activation of protein kinase B/Akt (110). 
Furthermore, resistin has been shown to inhibit AMP-activated kinase (AMPK) in liver and 
muscle (47, 111) and to activate suppressor of cytokine signalling 3 (SOCS-3) in mouse 
adipose tissue (110). AMPK is known to inhibit hepatic gluconeogenesis and stimulate 
muscle glucose uptake (112) and SOCS-3 is known to suppress insulin signalling in several 
tissues (113-115). These effects can explain in vivo experiments that administration of 
resistin to rodents either centrally (111) or peripherally (45, 111), or over-expression of 
resistin (116) increase glucose levels. 
 
1.8.2 Food intake 
Resistin gene expression in adipose tissue suggests that it may play a role in energy 
regulation because resistin mRNA levels are influenced by nutritional status, for example 
down-regulated by fasting and up-regulated by feeding (8). 
 
Tovar et al (43) assessed the effects of central resistin on food intake in rats. They found that 
ICV injection of resistin exerted an anorectic effect on food intake. This effect was transient 
as it was observed only during the first 90 minutes after the ICV injection. The acute 
anorectic effect of resistin was associated with changes in the neuropeptide genes expression 
involved in the central regulation of food intake. Resistin was associated with (i) decreased 
neuropeptide-Y and agouti-related protein expression and (ii) increased cocaine and 
amphetamine-regulated transcript gene levels in the arcuate nucleus of the hypothalamus 
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(117). These effects are similar to leptin (67). The results suggest that resistin and leptin 
might regulate food intake via similar pathways.  
 
1.8.3 Metabolism 
Central administration of resistin induced the expression of fat-promoting enzymes in the 
liver and adipose tissue in a nutrition-dependent manner, being increased in the liver of fed 
and in the adipose tissue of fasted rats suggesting that hypothalamic resistin can promote fat 
storage by increasing the lipid synthesis in the liver and WAT (117). 
 
Tovar et al (43) showed that although ICV resistin reduces food intake, repeated central 
administration of resistin over several days, did not lead to significant changes in body 
weight. Thus, resistin reduces energy intake by acting centrally to acutely reduce food intake 
but this may not be sufficient to reduce body weight, suggesting that resistin may alter 
energy expenditure. 
 
One of the important components of energy expenditure is thermogenesis in brown adipose 
tissue (BAT). The main function of BAT is heat production by transferring energy from food 
into heat. This physiological activity of the tissue is under the control of norepinephrine 
released from sympathetic nerves, acting on adrenergic receptors, predominantly β-3. The 
rate of thermogenesis is centrally controlled in the hypothalamus. When there is a need to 
increase the rate of heat production, a signal is transmitted via the sympathetic nervous 
system to the brown adipocytes. The intracellular pathways involve cAMP, protein kinase A 
and increased the activity of uncoupling protein-1 (UCP1, thermogenin). 
 
UCP1, a marker of thermogenesis, is a member of uncoupling proteins found in 
mitochondria in BAT, it allows for mitochondrial combustion of substrates, independent of 
24  
the production of ATP. The outcome is that an increased fraction of the food and the oxygen 
available in the blood is taken up by the tissue and combusted therein, leading to an 
increased heat production (118). 
 
There has been considerable discussion lately about the role of thermogenesis and BAT in 
metabolic regulation in humans. Until recently, BAT was believed to be present only in 
infants; however, it is now recognized that BAT is present and is metabolically active in 
adults (119). Stimulation of thermogenesis in BAT may have dramatic effects on energy 
expenditure because calculations show that activation of 40–50 g of BAT in humans could 
result in a 20% increase in energy expenditure (120) and could have dramatic effects on 
weight loss. 
 
The adipokine, leptin, is known to stimulate thermogenesis in BAT by increasing BAT SNA 
(63). Leptin also reduces fat tissue mass and lipid accumulation, preventing the development 
of obesity (121). In contrast, resistin promotes fat storage by increasing lipid synthesis (117), 
however, the role of resistin on energy expenditure or thermogenesis in BAT is not known 
(Fig 1.1). 
 
1.9 Summary  
In summary, resistin is an adipokine, originally identified in adipose tissue and its plasma 
levels are elevated in obesity. Resistin induces insulin resistance and affects energy 
homeostasis by reducing food intake. Plasma levels of resistin are correlated with the 
development and severity of heart failure, hypertension and myocardial infarction, 
suggesting that resistin may have cardiovascular effects, however, the mechanisms 
underlying such effects are unclear. Characteristics of obesity include impaired metabolic 
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regulation such as imbalance between energy intake and energy expenditure, and 
cardiovascular dysfunction such as increased SNA to the kidney and skeletal muscle 
vasculature. Prior to my work, it had not been investigated whether resistin affects SNA. 
This thesis investigates the effect of resistin on (i) SNA targeting the cardiovascular organs, 
(ii) thermogenesis in BAT and (iii) the intracellular signalling pathways mediating those 
effects. 
 
 
 
1.10 AIMS 
The specific aims of the present work are to investigate: 
1- The role of resistin on lumbar sympathetic nerve activity and the central sites in the 
hypothalamus that are activated by resistin. 
2- The role of resistin on renal sympathetic nerve activity and the intracellular 
mechanisms involved. 
3- The role of resistin on brown adipose tissue sympathetic nerve activity and the 
intracellular mechanisms involved.  
4- The effects of resistin on thermogenic markers in BAT and role of ERK1/2 in 
mediating the effects of resistin on thermogenesis in BAT. 
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Chapter 2: Materials and Methods 
2.1 Instrumentation  
2.1.1 Manufacture of blood vessel cannulae 
To measure blood pressure and allow intravenous infusion of drugs, cannulae were 
manufactured to be inserted into the femoral artery and vein. To manufacture the cannulae, 
two different sizes of polyvinyl chloride (PVC) tubings were used. The smaller tube 
(catalogue number 530010 – internal diameter of 0.28 mm and outer diameter of 0.61 mm; 
Biocorp, VIC, Australia) was inserted approximately 20 mm into a pre-cut 20 cm length of 
the larger bore tubing (catalogue number 530055- internal diameter 0.80 mm and outer 
diameter 1.20 mm, Biocorp, VIC, Australia) and the two were connected using Araldite ® 
Epoxy Resin (Selleys Pty Ltd; NSW, Australia) glue. The glue was moulded into a ball to 
assist in tying the cannula in place following implantation. The smaller tube was trimmed at 
a 45 ° angle so that it extended a minimum of 30-40 mm past the ball of glue (Figure 2.1) 
 
2.1.2 Manufacture of glass Micropipettes 
Glass micropipettes were made to allow intracerebroventricular injections. To manufacture 
the glass micropipettes a P-97 Flaming/Brown micropipette puller (Sutter Instrument 
Company, CA, USA) was used. These glass micropipettes (Accu-fill 90®, Clay Adams, 
Becton, Dickson and Co., NJ, USA) were placed in the micropipette puller machine. The 
puller was programmed (Program details: Heat 740; Pull 40; Velocity 50; Time duration 
110s) to produce pipettes with an external diameter of approximately 60 µm and an internal 
diameter of approximately 30 µm when the shaft was trimmed down to 12 mm in length 
(Figure 2.2). 
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Figure 2.1 – Photo of a typical blood vessel cannula. The tube of smaller bore is inserted 
approximately 20 mm into the larger bore tubing and held fast by Araldite ® Epoxy Resin 
glue. The glue was then moulded into a ball to assist in tying the cannula in place following 
implantation. The smaller PVC tube was trimmed at a 45°angle so that it extended a 
minimum of 30-40 mm past the ball of glue. 
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Figure 2.2- Glass micropipette used for intracerebroventricular microinjections. 
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2.1.3 Manufacture of electrodes 
For recording sympathetic nerve activity signals, a bipolar electrode was manufactured using 
two Teflon-insulated stainless steel wires (catalogue number: AGT1025, World Precision 
Instrument Inc., FL, USA). The tips of the bipolar electrode were bared from the Teflon-
insulation for about 5mm and were folded to form a hook. The electrode tips were 4 mm 
apart. The other end was soldered to two gold plated pins to allow connection to an 
amplifier. The electrode was insulated in a PVC tube (catalogue number 530055- internal 
diameter 0.80 mm and outer diameter 1.20 mm, Biocorp, VIC, Australia) to reduce electrical 
interference (Figure 2.3).  
 
2.1.4 Thermistor calibration 
Brown adipose tissue temperature was measured using a thermistor probe. 
The thermistor probe was connected to a multimeter (Fluke 73III, Fluke Australia, NSW, 
Australia) and calibrated to accurately measure the temperature between 20°C to 40°C using 
a water bath and a mercury thermometer.  
30  
 
 
Figure 2.3- Bipolar Teflon-insulated stainless steel electrode wire insulated in a polyvinyl 
chloride tube. 
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2.2 Surgical preparations of animals  
2.2.1 Animals and housing 
Male Sprague-Dawley rats were obtained from Monash University Animal Services 
(Victoria, Australia) and ARC (animal resources centre, W.A, Australia). Animals typically 
had a body weight ranging between 240-320 grams on the days of the experiments. The 
animals were housed 2-4 in a cage in a temperature-controlled room on a 12:12 hour 
light / dark cycle (lights on at 7:00 A.M.) in the Animal Facility (RMIT University, Victoria, 
Australia), where rat chow and tap water were available ad libitum. Animals were 
acclimatized for approximately 7 days prior to the experiment. 
 
All experimental protocols were performed in accordance with the Prevention of Cruelty to 
Animals Act 1986 (Australia). These protocols conform to (1) the “Guiding Principles for 
Research Involving Animals and Human Beings” (2) and the guidelines set out by the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 2007 
(National Health and Medical Research Council of Australia) and were approved by the 
Royal Melbourne Institute of Technology (RMIT) University Animal Ethics Committee. 
Every attempt was made to minimize animal suffering, discomfort and reduce the number of 
animals needed to obtain reliable results. 
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2.2.2 Cannulation of femoral artery and vein 
The cannulation of the femoral artery was performed to enable continuous monitoring of 
blood pressure, whilst the femoral vein was cannulated to enable infusion of urethane to 
maintain anaesthesia during the experiments. Under general gaseous anaesthesia (2.5–3%  
isoflurane in O2), the right groin region was shaved and swabbed with 70% alcohol before a 
5-7 mm incision was made through the skin over the femoral neurovascular bundle. The 
subcutaneous fascia was cleared by a blunt dissection to expose the underlying bundle, and 
the vessels separated by clearing the femoral sheath. The femoral vein was cannulated first. 
Two lengths of fine thread (silk 3/0, Dynek Pty, Australia) were passed under the vessel and 
pulled tight to elevate the vessel and temporarily stop the blood flow. A few drops of the 
local anaesthetic, lignocaine (Sigma Aldrich, NSW, Australia), were placed onto the vessel 
to be cannulated to avoid vasospasm.  Using very fine McPherson-Vannas 8cm scissors 
(World Precision Instruments Inc., FL, USA), a small cut, about one-third through the 
diameter of the vessel, was made in the vessel. Closed fine tweezers # 5 (World Precision 
Instruments Inc., FL, USA) were inserted into the cut and expanded slightly to enable the 
cannula tip to be introduced into the vessel. The tweezers were then withdrawn and the 
cannula, filled with heparinised saline (50 U/mL) was threaded 30-40 mm along the vessel 
and secured around the ball of glue of the cannula. The femoral artery was cannulated using 
a similar procedure as described. Upon completion of the cannulation procedures, the 
incision was closed using stiches (silk 0-USP, Dynek Pty, Australia). The free end of the 
arterial cannula was connected to a transducer for recording blood pressure using a 
PowerLab data acquisition system (ADInstruments, NSW, Australia). The heart rate was 
calculated from the arterial pressure pulse. The free end of the venous cannula was used for 
intravenous infusion. 
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2.2.3 Temperature recording  
BAT temperature 
Interscapular brown adipose tissue (BAT) was exposed through an incision in the nape of the 
neck. Temperature within the interscapular BAT was recorded by placing the tip of a 
thermistor probe into the interscapular BAT (Fluke 73III, Fluke Australia, NSW, Australia). 
The thermistor probe was secured by silk suture (silk 0-USP, Dynek Pty, Australia) to the 
skin. The probe was calibrated in a water bath using a mercury thermometer.  
 
Body core temperature 
Body core temperature was measured by a thermometer placed in the rectum (Fluke 52II 
thermometer, Fluke Australia, NSW, Australia). The temperature was measured at 15 minute 
intervals. 
 
2.2.4 Nerve dissection and recording 
Lumbar nerve  
After a midline abdominal incision and retraction of the intestines, the abdominal aorta and 
vena cava were gently pulled aside to expose the lumbar nerve. The left sympathetic trunk 
lies on the psoas muscle located under the aorta. The left lumbar postganglionic sympathetic 
nerve trunk was identified and dissected free of surrounding tissue. With the aid of an 
operating microscope, the nerve was placed onto the bared tips of two Teflon-coated silver 
wire electrodes. Lumbar nerve activity was made audible with an audio amplifier. When 
optimal nerve activity was confirmed by observing the rhythmic bursts of nerve traffic, the 
wires of the electrode and the isolated lumbar sympathetic nerve were embedded in a two-
component silicone gel (Kwik-Cast Sealant, WPI) to insulate the nerve-electrode junction 
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from surrounding tissue. Once the silicone gel had hardened, two small pieces of gauze were 
placed around the electrode to support the electrode position. The incisions were sutured 
closed and the free end of the wire electrode was connected to the recording equipment.  
 
Brown adipose tissue nerve 
Rats were placed prone, and the head was mounted in a Stoelting stereotaxic frame 
(Stoelting, IL, USA). To avoid hypothermia and maintain the body core temperature, 
animals were placed on an insulated heat pad. Interscapular brown adipose tissue (BAT) was 
exposed through an incision in the nape of the neck. The fat pad was divided along the 
midline and reflected laterally.  The postganglionic BAT sympathetic nerve which is a fine 
branch of the intercostal nerves that innervate the right interscapular BAT was identified and 
dissected free of surrounding tissue under mineral oil to prevent the nerve from dehydration. 
The nerve was transected where it entered BAT and placed onto the bared tips of two 
Teflon-coated silver wire electrodes. The nerve activity was made audible with an audio 
amplifier. The optimal nerve activity was confirmed by observing the rhythmic bursts of 
nerve traffic responding to changes in body core temperature.  
 
Renal nerve 
After a flank incision, the left kidney was exposed retroperitoneally. With the aid of 
retractors, the muscle and fat tissue were pulled aside. With the aid of an operating 
microscope, a renal nerve was carefully dissected free of surrounding tissue under mineral 
oil. The distal end of the nerve was cut and the nerve was placed onto the bared tips of two 
Teflon-coated silver wire electrodes. Renal nerve activity was made audible with an audio 
amplifier. When optimal nerve activity was confirmed by observing the rhythmic bursts of 
nerve traffic, the wires of the electrode and the isolated renal sympathetic nerve were 
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embedded in a two-component silicone gel (Kwik-Cast Sealant, WPI) to insulate the nerve-
electrode junction from surrounding tissue. 
 
The sympathetic nerve activity of either the lumbar, the BAT or the renal nerve was 
amplified using a low-noise differential amplifier (models ENG 187B and 133, Baker 
Institute, Victoria, Australia), filtered (band pass 100–1,000 Hz), rectified, and integrated (at 
2.5 s intervals for the BAT SNA and 0.5 s intervals for lumbar and renal SNA). The signal 
was recorded using a PowerLab data acquisition system (ADInstruments, NSW, Australia). 
At the end of the experiment, nerve activity was verified as sympathetic postganglionic 
nerve activity by observing an elimination of activity after IV injection of a sympathetic 
ganglion blocker (hexamethonium, 10 mg/kg, Sigma, Australia). Background noise was 
determined by post-mortem measurements. 
 
2.2.5 Microinjection into the lateral ventricle (ICV) 
Each animal was placed prone, and the head was mounted in a Stoelting stereotaxic frame, 
such that bregma and lambda were positioned on the same horizontal plane. For exposure of 
the dorsal surface of the brain, a hole (4 mm diameter) centred 0.7 mm caudal and 1.8 mm 
lateral from bregma, was drilled into the skull. After the drilling procedure, the hole was 
covered with cotton wool soaked in normal saline to prevent drying of the exposed surface. 
Injections were made unilaterally using a fine glass micropipette (50–70 µm tip diameter) 
inserted into the lateral brain ventricle  (stereotaxic coordinates: 0.7 mm caudal to bregma, 
1.8 mm lateral to midline, and 3.7 mm ventral to the surface of the dura). After the 
microinjection, the micropipette was left in place for 1 min. At the end of the experiment a 
small amount of pontamine sky blue was microinjected using the same coordinates to 
confirm microinjection into the lateral ventricle (Figure 2.4).  
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Figure 2.4 – Rats were positioned prone and the head was mounted and stabilised in a 
Stoelting stereotactic frame. 
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2.2.6 Tissue collection  
At the end of the experiments, animals were euthanized and brain and brown adipose tissue 
were collected. 
Brain 
Following a midline incision of the skin extending approximately from between the eyes to 
the level of T2, the muscle layers were scraped away to reveal the occipital bone and 
vertebrae. Using rongeurs, the spongy part of the occipital bone was carefully removed to 
reveal the cerebellum, and then the cerebral hemispheres and brainstem. The dura mater was 
peeled back from the brain surface, followed by two transverse cuts, one at the level of the 
olfactory bulb and the other at the caudal end of the medulla. A long thin spatula was used to 
raise the brain and the optic nerves were cut. Then the brain was carefully removed and 
transferred into fixative solution (see section 2.3). 
Brown adipose tissue 
BAT was exposed by an incision in the nape of the neck. The fat pad was divided along the 
midline and reflected laterally. Several small pieces of the BAT (about 100mg) were 
carefully dissected and rapidly excised, frozen in liquid nitrogen and stored at -80°C. 
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2.2.7 Drugs 
Recombinant rat resistin (lot#L16251/F, L28370,), recombinant rat leptin 
(lot#AQP2411031), LY294002 (lot#3-S13213W) and U0126 (lot#3-Z5175W) were 
purchased from Sapphire Biosciences (Australia). DMSO (lot#109K2350) was obtained 
from Sigma (Australia). Artificial cerebrospinal fluid contained NaCl 124mM, KCl 3.0mM, 
NaH2PO4.2H2O 1.3mM, MgCl2.6H2O 2.0mM, NaHCO3 26mM, glucose 10mM, CaCl2 
2.0mM in Milli-Q water, buffered with carbogen. 
 
2.3 Immunohistochemistry experiments 
2.3.1 Fixing the brain 
After removing the brain from the skull, brains were fixed in the fixative solution, containing 
4% PFA for four hours and then placed in phosphate buffered saline (PBS) containing 20% 
sucrose solution and stored at 4 ºC. 
 
2.3.2 Sectioning of the rat brain 
Serial coronal sections (40 µm thick) of the brain were cut using a a Leica CM 1900 cryostat 
(Leica Microsystems Nussloch GmbH, Nussloch, Germany). One in five sections was 
collected, placed onto gelatine-coated slides, dried for 2 hours at room temperature and then 
processed immunohistochemically to detect Fos protein using standard 
immunohistochemical procedures. 
 
39  
2.3.3 Immunohistochemical Staining procedures 
To identify activated neurons by using Fos as a marker of neuronal activation, 
immunohistochemistry for the protein Fos was performed. The sections were incubated and 
processed using standard immunohistochemical procedures as follows. Sections underwent 
washes in PBS (3 times for 5 min duration) between each incubation. Endogenous 
peroxidase activity was destroyed by incubating with 0.5% H2O2 for 30 minutes. The 
sections were incubated in 10% normal goat serum (NGS) for 60 minutes prior to 0.5% 
Triton X-100 (10 minutes) to facilitate antibody penetration. The sections were incubated in 
anti-Fos primary antibody (rabbit polyclonal IgG , c-Fos (K-25): sc-253, Santa Cruz 
Biotechnology, CA, USA; dilution: 1:400) for 24 hours at room temperature. The sections 
were incubated for 1 hour with (i) biotinylated secondary antibody (1:600, Anti rabbit raised 
in goat, B8895, Sigma Aldrich, Australia) and subsequently (ii) Extravidin (1:400, Sigma 
Aldrich, Australia) for 1 hour. Both incubations were at room temperature. Then the sections 
were incubated in 0.05% 3,3′-diaminobenzidine hydrochloride (DAB; sigma Aldrich, 
Australia) in Tris buffer (0.05 M, pH 7.6) for 10 minutes. The reaction was initiated by 
adding 5 µl of 17.5% hydrogen peroxide and terminated by washes with fresh Tris buffer. 
Finally the sections were allowed to dry and were coverslipped using Depex mounting 
medium. 
 
2.3.4 Photomicroscopy  
Photographic images were acquired using a digital camera (Sensi Cam, PCO CCD Imaging, 
Kelheim, Germany) on an Olympus BX60 microscope (Olympus Inc, PA, USA). The digital 
images obtained were imported into Adobe Photoshop ® 7 (Adobe Systems Incorporated, 
CA, U.S.A) and the contrast and brightness were modified for presentation purposes. 
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2.4 Real time PCR 
2.4.1 RNA Extraction and Quantification by real time PCR 
 Brown adipose tissue RNA extraction was performed using a TRIzol-based kit (Invitrogen, 
Melbourne, Australia, Cat No 12183-018A). Approximately 30 mg of brown adipose tissue 
was placed in 500 µl of TRIzol and homogenised with a handheld, motorised Teflon pestle. 
Samples were allowed to stand for a few minutes, after which chloroform (1/5 volume 
TRIzol) was added and the sample vigorously shaken. Samples were allowed to stand for 5 
min and spun at 12,000g for 15 min at 4ºC after which the upper aqueous phase was 
transferred to a new tube. The aqueous phase was precipitated by mixing with isopropanol 
alcohol (1/2 volume TRIzol). Samples were incubated at room temperature for 10 min and 
then centrifuged at 12,000g for 15 min at 4ºC. The supernatant was removed and the 
resulting pellet was washed with 200 µl of 70% ethanol in diethylpyrocarbonate-treated 
water. After elution through a spin cartridge, RNA was extracted and then quantified using a 
QUANT-iT analyser kit (Invitrogen, Melbourne, Australia, Cat No Q32852).  The RNA 
samples were diluted as appropriate to equalise concentrations, and stored at -80˚C for 
subsequent reverse transcription. 
 
First-strand complementary DNA (cDNA) synthesis was performed using commercially 
available TaqMan Reverse Transcription Reagents (Invitrogen, Melbourne, Australia) in a 
final reaction volume of 20 µl.  All RNA and negative control samples were reverse 
transcribed to cDNA in a single run from the same reverse transcription master mix.  A 
serially diluted pooled RNA sample from the control group was produced and also included 
to ensure efficiency of reverse transcription and for calculation of a standard curve for real-
time quantitative polymerase chain reaction (RT-PCR).  Quantification of mRNA (in 
duplicate) was performed on a 72-well Rotor-Gene 3000 Centrifugal Real-Time Cycler 
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(Corbett Research, Mortlake, Australia).  Taqman-FAM-labelled primer/probes for UCP1 
(Cat No. Rn 00562126_m1), PGC-1α (Cat No. Rn00580241_m1) and Deiodinase Type II 
(Cat No. Rn00581867_m1) were used in a final reaction volume of 20 µl.  PCR conditions 
were 2 min at 50 ºC, 10 min at 95 ºC then 40 cycles of 95 ºC for 15 s and 60 ºC for 60 s.  18S 
ribosomal RNA (18S rRNA) (Cat No. Hs99999901_s1) was used as a housekeeping gene to 
normalize threshold cycle (CT) values. The relative amounts of mRNAs were calculated 
using the relative quantification (∆∆CT) method (122). 
 
2.5 Statistical analysis 
2.5.1 Mean arterial pressure and heart rate 
The basal levels of MAP and HR prior to ICV injections were compared between the 
treatment and control groups using Student’s unpaired t-test. Changes in MAP and HR were 
compared between groups in each experimental series by using two-way ANOVA with 
repeated measures. All results are expressed as means ± SE. P<0.05 was considered to be 
statistically significant. 
 
2.5.2 Sympathetic nerve activity 
The integrated SNA was calculated over a period of 1-2 minutes at each time point, 
subtracted from the noise level and expressed as a percentage of the resting level prior to the 
ICV injections.  Changes in SNA were compared between groups in each experimental 
series by using two-way ANOVA with repeated measures. All results are expressed as 
means ± SE. P<0.05 was considered to be statistically significant. 
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2.5.3 BAT & Body Core Temperature 
The basal levels of body core temperature and BAT temperature prior to ICV injections were 
compared between the groups using Student’s unpaired t-test. Changes in body core 
temperature and BAT temperature were compared between groups in each experimental 
series by using two-way ANOVA with repeated measures. All results are expressed as 
means ± SE. P<0.05 was considered to be statistically significant. 
 
2.5.4 Immunohistochemistry (FOS) 
Fos-positive cell nuclei were counted unilaterally in 3 sections containing the  
paraventricular nucleus,  (Anterior, mid and caudal levels), 2 sections containing the 
supraoptic nucleus (at the anterior and mid levels of the paraventricular nucleus) , 2 sections 
containing the arcuate nucleus (located within 0.5mm caudal to the paraventricular nucleus) 
and 1 section containing the subfornical organ. The overall mean number of Fos-positive 
nuclei in each area were calculated and compared between the resistin-treated and the 
control group using Student’s unpaired t-test.  
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Chapter 3: Effects of resistin on blood pressure, heart 
rate, lumbar and renal sympathetic nerve activity  
3.1 Introduction 
Resistin has been linked to cardiovascular disease and there is emerging epidemiological 
evidence showing that plasma resistin levels are associated with the development and 
severity of heart failure (19, 20, 22, 23, 123) and hypertension (21, 24, 77, 78).  A positive 
association between plasma resistin levels and hypertension, measured using 24 hours 
ambulatory blood pressure monitoring, has been observed (21, 24). Interestingly, increased 
plasma resistin levels has been observed in a young healthy population with positive family 
history for essential hypertension (77). Furthermore,  a study on the population of women 
without previous history of hypertension or diabetes, suggested that plasma resistin levels 
may have a predictive value since plasma resistin levels were associated with the risk of 
developing hypertension over the 14 years of follow up (78).  
 
A characteristic of both heart failure and hypertension is an elevation of sympathetic nerve 
activity (SNA) (4, 61). Similarly in obesity and metabolic syndrome, there is an increase in 
sympathetic nerve activity to the skeletal muscle blood vessels and to the kidneys (3, 4, 56). 
For example many studies indicate that obese humans have about 50-100% higher levels of 
muscle sympathetic nerve activity compared with their non-obese peers (56). In obesity, 
body mass index is independently correlated with renal norepinephrine spillover rate (57) 
and sympathetic nerve activation (4). This may contribute to the cardiovascular 
complications observed in obesity, which is a recognized risk factor for cardiovascular 
disease, hypertension and type 2 diabetes. 
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Leptin is another adipokine which has some similarities to resistin. Plasma levels of leptin 
are increased in obesity and cardiovascular disease (124). Leptin is known to increase 
sympathetic nerve activity to the kidney, adrenal gland and skeletal muscles vasculature (5, 
69). This increased SNA is now believed to be an important contributor to sympathetic over-
activity observed in obesity and obesity-induced hypertension (70, 71).  
 
Similar to leptin, plasma levels of resistin are elevated in obesity, metabolic syndrome and 
cardiovascular disease (12-16, 19-21, 24, 47). Whether resistin can influence SNA to 
different organs has not been investigated to date. The primary aims of this study were to 
determine the acute effects of resistin on sympathetic nerve activity to the skeletal muscle 
vasculature (lumbar, SNA) and to the kidneys (renal SNA), end-organs that are important in 
cardiovascular regulation and in fluid and electrolyte balance. Blood pressure and heart rate 
were also monitored. Since the receptor for resistin is not clearly identified to date, I 
investigated the distribution of the protein Fos, a marker of increased neuronal activity, in 
the hypothalamus to gain an insight into the potential central sites of action of resistin. 
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3.2 Methods 
3.2.1 Experimental protocols 
Rats were fasted overnight before the experiment. On the day of the experiment, anesthesia 
was induced using isoflurane gas (2.5–3%) in O2. The femoral vein was cannulated to enable 
infusion of the drugs and to maintain anesthesia (iv urethane 1–1.4 g/kg initially, followed 
by supplemental doses of 0.05 g/kg as required). The femoral artery was cannulated to allow 
the measurement of arterial pressure. Mean arterial pressure and heart rate were calculated as 
explained in detail in Chapter 2 (Section 2.2). 
 
Intracerebroventricular (ICV) administration: In these experiments the mean arterial 
pressure, heart rate and either lumbar SNA or renal SNA were recorded for 3 to 4 hours 
following the ICV administration of resistin (7µg in 7µl) or vehicle (artificial cerebrospinal 
fluid 7µl). 
  
Intravenous administration: In three urethane-anaesthetized rats, resistin (7µg in 7µl) was 
administered intravenously via a femoral vein. Mean arterial pressure, heart rate and lumbar 
SNA were recorded for four hours. 
 
In all experiments, resting levels were recorded for at least 10 min prior to the injection of 
resistin or vehicle. Following the injections, all variables were monitored continuously and 
recorded every 15 minutes over the observation period.  
 
3.2.2 Immunohistochemistry for Fos protein 
On completion of the ICV administration of resistin / vehicle in the experimental series 
recording lumbar SNA, the animals were euthanized with an overdose of pentobarbitone 
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(300mg/kg, IV) and were decapitated. The brains were removed, cut and processed for 
immunohistochemistry to detect Fos protein as explained in Chapter 2 (Section 3). 
 
3.2.3 Statistical analysis 
The mean arterial pressure and heart rate data from the two experimental series monitoring 
lumbar SNA and renal SNA have been combined because no differences were observed 
between the experimental series in these variables. The resting levels of mean arterial 
pressure and heart rate before the injections were compared between the resistin and control 
groups using Student’s unpaired t test. The integrated SNA was calculated over a period of 
1-2 minutes at each time point and expressed as a percentage of the resting level prior to the 
injections. Changes in mean arterial pressure, heart rate, lumbar SNA or renal SNA were 
compared between groups in each experimental series by using two-way ANOVA with 
repeated measures. Quantification of Fos-positive nuclei was performed as explained in 
chapter 2 section 5.4. All results are expressed as means ± SE. P < 0.05 was considered to be 
statistically significant. 
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3.3 Results 
3.31 Effect of resistin on mean arterial pressure  
The resting levels of mean arterial pressure before the ICV administration of vehicle and 
resistin are shown in the bar graphs in Fig. 3.1. There were no significant differences in the 
resting levels of mean arterial pressure between the two groups (Fig. 3.1). After the 
administration of resistin, there was an acute increase in mean arterial pressure by 
approximately 5 mmHg within the first 15 minutes but returned to resting levels soon after 
(Fig 3.1). This effect was not significantly different from the control group (Fig. 3.1).  
 
3.3.2 Effect of resistin on heart rate 
The resting levels of heart rate before the ICV administration of vehicle and resistin are 
shown in the bar graphs in Fig. 1. There were no significant differences in the resting levels 
of heart rate between the two groups (Fig. 3.1). After the ICV injection of resistin, the effect 
on heart rate was quite variable over the 4-h observation period (Fig. 3.1). After vehicle 
administration, heart rate was variable and not markedly affected. There was no significant 
difference in the heart rate responses between the two groups. 
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Figure 3.1 
Left panels: Resting mean arterial pressure (MAP) and heart rate prior to 
intracerebroventricular (ICV) administration of resistin (7µg, n=15) or vehicle (artificial 
CSF, aCSF,  n= 11) are shown in the bar graphs. Right panels: Changes in MAP and changes 
in heart rate induced by ICV resistin or vehicle (aCSF) over time. 
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3.3.3 Effect of resistin on lumbar SNA 
Original recordings of the lumbar SNA from representative animals treated with ICV resistin 
or vehicle are shown in Fig 3.2A.  ICV resistin increased lumbar SNA gradually over the 
observation period and reached a maximum increase of approximately 40% (Fig 3.2B). This 
response was significantly different compared to the vehicle-treated group (F(1,176) = 
11.85, p<0.05) (Fig 3.2). 
  
3.3.4 Effect of resistin on Renal SNA 
Original recordings of the renal SNA from representative animals treated with ICV resistin 
or vehicle are shown in figure 3. In the vehicle-treated group, there was a small reduction in 
renal SNA over time, which may be due to anaesthesia. In the treatment group, ICV resistin 
increased renal SNA within 15 minutes and was sustained over the observation period. The 
maximum increase in renal SNA was approximately 40% (Fig 3). This response was 
significantly greater than that observed in the vehicle-treated group (F(1,120) = 5.932 , 
P<0.05) (Fig 3.3).  
3.3.5 Effects of intravenous resistin  
To determine whether leakage of resistin from the cerebral ventricles into the systemic 
circulation could account for the changes described, we injected resistin intravenously at the 
same dose (7ug) as that administered ICV.  Intravenous resistin did not significantly change 
mean arterial pressure, heart rate or lumbar SNA compared to resting levels recorded prior to 
resistin (Fig 3.4). 
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Figure 3.2 See the next page for figure legends 
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Figure 3.2 
Panel A: Screen capture of the raw recordings of lumbar sympathetic nerve activity (lumbar 
SNA) and integrated lumbar SNA (ILSNA) before and after resistin (7µg) or vehicle 
(artificial CSF) administered into the lateral brain ventricle.  ∟, horizontal bar =2 seconds, 
vertical bar =100mV (lumbar SNA) and 10mV.s (ILSNA).  *p<0.05 
 
Panel B: The percent changes in lumbar SNA from resting levels over four hours following 
administration of resistin (7µg; n=6) or control (artificial CSF; n=7).  
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Figure 3.3 See the next page for figure legends 
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Figure 3.3 
(A)  Screen capture of raw recordings of renal sympathetic nerve activity (RSNA) and 
integrated renal SNA (IRSNA) before and after resistin (7µg) or vehicle (artificial CSF) 
administered into the lateral brain ventricle. ∟, horizontal bar =2 seconds, vertical bar 
=200mV (RSNA) and 10mV.s (IRSNA).   
 
(B)  The percent changes in renal sympathetic nerve activity (RSNA) from resting levels 
over time following administration of resistin (7µg; n=7) or vehicle (artificial CSF; n=5). 
*p<0.05 
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Figure 3.4 
Average mean arterial pressure, heart rate and lumbar sympathetic nerve activity (SNA) pre 
and at 4 hours post intravenous resistin (7ug, n=3). Lumbar SNA is expressed as % of the 
resting level. 
 
 
55  
 
3.3.6 Effects of resistin on Fos, a marker of increased neuronal activation 
Central administration of resistin significantly increased Fos production in most of the 
hypothalamic nuclei examined. In the paraventricular nucleus, Fos was detected in both the 
magnocellular and parvocellular subnuclei (Fig 3.5). Overall there was a 7 fold increase in 
the number of Fos-positive cell nuclei counted in the paraventricular nucleus following the 
administration of resistin compared to the vehicle-treatment (Fig 3.6). Similarly, in the 
supraoptic nucleus, resistin significantly increased Fos production by 7 fold (Fig 3.5 and 
3.6). In the subfornical organ, the numbers of Fos-positive nuclei were increased by 30 fold 
with resistin treatment (Fig 3.5 and 3.6) and this was significantly different from vehicle-
treated group.  In the arcuate nucleus, there was no significant difference in the numbers of 
Fos-positive cell nuclei counted in the resistin-treated group compared to vehicle (Fig 3.5 
and 3.6). 
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Figure 3.5 See the next page for figure legends 
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Figure 3.5  
Photomicrographs showing Fos-positive cell nuclei in hypothalamic nuclei from rats 
administered resistin (7µg) (B,D,F,H) or vehicle (artificial CSF) (A,C,E,G) administered into 
the lateral brain ventricle. Abbreviations: PVN, paraventricular nucleus; ARC, arcuate 
nucleus; SFO, subfornical organ; SON, supraoptic nucleus; III, third ventricle.  Bar 
represents 100 µm. 
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Figure 3.6 
Fos-positive cell nuclei counted in the hypothalamic subfornical organ (SFO), supraoptic 
(SON), paraventricular (PVN) and arcuate (ARC) nuclei from brain of rats treated with 
resistin (7µg; n=6) or control (artificial CSF; n=6). * P<0.05, ** P<0.005 resistin vs control. 
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3.4 Discussion 
 
The present study is the first to directly measure the effects of resistin administration on 
sympathetic nerve activity.  The key findings of the study show that ICV resistin increased 
lumbar and renal SNA. I did not observe any significant effects on blood pressure and heart 
rate.  
 
In patients and animal models of type 2 diabetes and obesity, sympathetic nerve activity to 
the skeletal muscle vascular beds and kidney is increased and this has been suggested to 
contribute to the incidence of cardiovascular disease in patients with those conditions (125), 
(61, 126) .  Resistin has been linked to cardiovascular disease and there is emerging 
epidemiological evidence showing that plasma resistin levels are associated with the 
development and severity of heart failure (17-20, 22, 23, 123).  A correlation between 
plasma resistin levels and hypertension has also been highlighted (21, 24, 25). Thus, resistin 
may contribute to cardiovascular complications but the mechanisms involved are unknown. 
In the present study, we found that acute intracerebroventricular administration of resistin 
induced a significant increase in lumbar SNA. Since muscle SNA is elevated in obesity and 
diabetes (61, 125, Barretto, 2008 #39), the effect of resistin we have observed may be a 
potential contributing factor to the cardiovascular complications associated with resistin.  
 
An increase in lumbar SNA has also been observed with the adipokine, leptin, administered 
into the cerebral ventricles (127). Leptin also increased sympathetic nerve activity to other 
vascular beds and elicited a concomitant rise in blood pressure. We investigated lumbar 
SNA since muscle sympathetic nerve activity is increased in obese patients (60), a condition 
in which plasma resistin levels are elevated (13-16). Abdominal visceral adiposity, in 
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particular, is closely associated with increased muscle SNA (60). Both lumbar SNA and 
muscle SNA are indicative of sympathetic nerve activity to the skeletal muscle vasculature. 
 
This study showed for the first time that resistin acts centrally to increase SNA directed at 
the kidney, a key organ in regulating electrolyte balance and blood pressure. There is a well-
recognised link between obesity and hypertension, but the mechanisms responsible for the 
hypertension in obese individuals is not known.  In obesity, noradrenaline spillover studies 
suggest there is an abnormal elevation in renal SNA.  The kidney is a key organ in 
cardiovascular regulation and increased renal SNA increases sodium retention, alters renal 
haemodynamics, increases renin release and activation of the renin angiotensin system, 
(128). It is interesting to speculate that since resistin and leptin have sympatho-excitatory 
effects on renal SNA, the increased levels of resistin and leptin observed in obesity, could 
contribute to the elevated renal SNA and thereby to the altered fluid and electrolyte balance 
observed with excess weight gain (3, 129).  
 
In the present studies, acute administration of resistin did not significantly increase blood 
pressure. Perhaps resistin may not elicit a generalised increase in sympathetic nerve activity 
to cardiovascular tissues such that the increased lumbar and renal sympathetic nerve activity 
is offset by reductions in other outputs. This requires further investigation. It is also possible 
that baroreceptor reflex responses are sufficiently activated and act to oppose an effect of 
resistin on blood pressure. It should also be noted that we investigated the acute effects of 
ICV resistin, and the effects of chronic administration of resistin on blood pressure and heart 
rate need to be investigated. Interestingly, the adipokine, leptin, has similar effects to resistin 
and significantly increases lumbar and renal sympathetic nerve activity (5, 63). Leptin has 
been reported to have variable effects on blood pressure when acute and chronic 
administrations of this adipokine were compared (130).   
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The effects observed following ICV resistin were centrally mediated since intravenous 
administration of the same dose of resistin did not have marked effects.  The receptor for 
resistin and the central sites of action of resistin are unknown.  Previous studies using Fos as 
a marker of increased neuronal activation suggested that the arcuate nucleus may be a site in 
which neurons are activated by resistin (43).  This was only observed in fasted rats (48 
hours). No other hypothalamic area showed increased Fos immunoreactivity in that study 
(43).  In mice, central administration of resistin has been found to increase Fos production in 
the hypothalamus, namely the arcuate, paraventricular and dorsomedial hypothalamic nuclei 
(131).  In our present work we found increases in Fos immunoreactivity in the hypothalamic 
paraventricular, supraoptic and subfornical nuclei but no significant increase in the arcuate 
nucleus and dorsomedial hypothalamus (data not shown).  Our work in rats was performed 
in anesthetised animals and this could complicate interpretation of the results. Species 
differences, whether the animals were fasted, and the duration of fasting may also account 
for some of the differences observed between reports. Since the receptors for resistin have 
not been clearly identified as yet, unequivocal confirmation of the sites of action of resistin 
in the hypothalamus awaits further investigations.  
 
3.5 Methodological aspects of the study 
The dose of resistin (7µg) used in this study was chosen based on previous studies in which 
ICV resistin at a dose of 10µg significantly influenced the food intake but had no effect at 
lower doses (1 and 5µg) (43). A similar dose has also been used in studies investigating the 
effects on sympathetic nerve activity of intracebreventricular administration of leptin. I have 
also observed that similar doses of resistin and leptin can increase renal sympathetic nerve 
activity (data not shown).  Whether the dose used in the present study is physiologically 
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relevant rather than pharmacological is pertinent since the normal plasma concentration of 
resistin is in the low ng/ml range rising approximately 10 fold in obese individuals (e.g. 35-
40ng/ml). However, it is interesting to note that a similar range of concentrations of leptin 
are found in humans (15, 132), but µg doses are required to be administered 
intracerebroventricularly in rodents to induce changes in renal sympathetic nerve activity.  
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Chapter 4: Intracellular mechanism mediating the effects 
of resistin on renal sympathetic nerve activity 
4.1 Introduction 
Resistin acting within the brain, increases lumbar and renal sympathetic nerve activity (133), 
which innervate the hindlimb vasculature and the kidneys respectively. The intracellular 
signalling pathways mediating resistin’s actions on sympathetic nerve activity are not 
known. This contrasts with our knowledge of the actions of resistin on cell growth, 
differentiation, metabolism and intracellular trafficking, which involve the enzymes 
phosphatidylinositol 3-kinases (PI 3-Kinase) and extracellular regulated kinases (ERK) 1/2. 
PI 3-Kinases are a family of cellular enzymes which have been shown to mediate resistin’s 
effects including sprouting in murine aortic explants, migration of murine endothelial cells 
and the release of growth hormone from pituitary somatotropes in vitro (134, 135). ERK 1/2 
has been found to mediate hypertrophy of rat neonatal myocytes, proliferation of human 
endothelial cells and increased expression of the transporter GLUT 1 in trophoblasts, 
induced by resistin (82, 136, 137). PI 3-Kinase and ERK 1/2 are involved in sympathetic 
nerve activity responses as shown by the critical role of PI 3-Kinase in mediating the 
changes in renal sympathetic nerve activity induced by central administration of leptin 
(Morgan et al. 2008), and the lumbar sympathetic nerve activity changes induced by insulin 
(138).  ERK1/2 activation mediates the changes induced by leptin, and insulin, on 
sympathetic nerve activity to brown adipose tissue (63, 138).  
 
The aim of the present work was to determine whether PI 3-Kinase or ERK1/2 was involved 
in mediating the action of resistin on renal sympathetic nerve activity. 
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4.2 Methods 
4.2.1 Experimental protocols 
Rats were fasted overnight before the experiment. On the day of the experiment, anesthesia 
was induced using isoflurane gas (2.5–3%) in O2. The femoral vein was cannulated to enable 
infusion of the drugs and to maintain anesthesia (iv urethane 1–1.4 g/kg initially, followed 
by supplemental doses of 0.05 g/kg as required). The femoral artery was cannulated to allow 
the measurement of arterial pressure. Mean arterial pressure and heart rate were calculated as 
explained in details in the method chapter (Chapter 2, section 2.2). 
 
Intracerebroventricular (ICV) administration: In these experiments the mean arterial 
pressure, heart rate and renal SNA were recorded. The PI 3-Kinase inhibitor (LY294002, 5 
µg in 2µl) or The ERK1/2 inhibitor (U0126, 7µg in 2µl) was administered ICV followed 15 
minutes later by resistin (7µg in 7µl) or vehicle (artificial cerebrospinal fluid 7µl) and the 
responses were monitored for 3 hours. DMSO (2µl) was used as a vehicle for LY294002 and 
U0126. 
 
In all experiments, resting levels were recorded for at least 10 min prior to the injection of 
resistin or vehicle. Following the injections, all variables were monitored continuously and 
recorded every 15 minutes over the observation period.  
 
4.2.2 Statistical analysis 
The resting levels of mean arterial pressure & heart rate prior to the injections were 
compared between groups using Student’s unpaired t-test.  The integrated SNA was 
calculated over a period of 1-2 minutes at each time point and expressed as a percentage of 
the resting level prior to the injections. Changes in mean arterial pressure, heart rate and 
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renal SNA were compared between groups in each experimental series by using two-way 
ANOVA with repeated measures. All results are expressed as means ± SE. P < 0.05 was 
considered to be statistically significant. 
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4.3 Results 
4.3.1 Role of PI 3-Kinase and ERK1/2 signalling pathways in mediating the action of 
resistin on blood pressure and heart rate 
The resting levels of mean arterial pressure and heart rate prior to the ICV administration of 
resistin in the presence of PI 3-Kinase inhibitor (LY294002) or ERK1/2 inhibitor (U0126) 
are shown in the bar graphs in figure 4.1.  
 
There was a statistically significant difference in baseline mean arterial pressure between the 
groups overall (F(3,20) = 6.251, p<0.05). Post hoc analysis detected a significant difference 
between the group administered vehicle + resistin compared to the group administered 
U0126 + resistin (p<0.05) (Fig 4.1). Additionally, there was a significant difference between 
the group administered LY294002 + resistin compared to the group administered U0126 + 
resistin (p<0.05) (Fig 4.1). There was also a statistically significant difference in baseline 
heart rate between the groups overall (F(3,20) =4.253, p<0.05), and post hoc analysis only 
detected a significant difference between the group administered LY294002 + resistin 
compared to the group administered vehicle (p<0.05) (Fig 4.1). 
 
The effect of LY294002 or U0126 alone on mean arterial pressure and heart rate was not 
significantly different from vehicle (data not shown). Resistin did not elicit any significant 
change in mean arterial pressure or heart rate and this was not significantly affected by pre-
treatment with LY294002 or U0126 (Fig 4.1).  
67  
Ve
hic
le 
+ 
Re
sis
tin
LY
29
40
02
 
+ 
Re
sis
tin
U0
12
6 +
 
Re
sis
tin
Co
ntr
ol
0
50
100
150 *
*
Re
st
in
g 
M
AP
 
(m
m
Hg
)
0 50 100 150 200
-10
0
10
20 LY294002 + Resistin
Vehicle + Resistin
U0126 + Resistin
Control
Role
Ch
an
ge
s 
in
 
M
AP
 
(m
m
H
g)
Ve
hic
 
+ 
Re
sis
tin
LY
29
40
02
 
+ 
Re
sis
tin
U0
12
6 +
 
Re
sis
tin
Co
ntr
ol
0
100
200
300
400
500 *
Re
s
tin
g 
He
a
rt
 
Ra
te
 
(b/
m
in
)
0 50 100 150 200
-40
-20
0
20
40
LY294002 + Resistin
Vehicle + Resistin
U0126 + Resistin
Control
Time (min)
Ch
an
ge
s 
in
 
H
e
ar
t R
at
e
 
(b/
m
in
)
 
Figure 4.1 
Left panels: Resting mean arterial pressure (MAP) and heart rate prior to 
intracerebroventricular (ICV) administration of resistin (7µg) or vehicle (artificial CSF, 
aCSF) are shown in the bar graphs. Right panels: Changes in MAP and changes in heart rate 
induced by ICV resistin or vehicle (aCSF) over time. Fifteen minutes prior to resistin 
administration, the rats received an ICV injection of either (i) DMSO (2µl, n=7), (ii) ERK1/2 
inhibitor (U0126, 7µg, n=5) or (iii) PI 3-Kinase inhibitor (LY294002, 5µg, n=5). DMSO 
(2µl, n=5) was also injected ICV fifteen minutes prior to the vehicle (aCSF). 
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4.3.2 Role of PI 3-Kinase signalling pathway in mediating the action of resistin on 
renal SNA 
Original recordings of the renal SNA from a representative animal treated with ICV resistin 
in the presence of the PI 3-Kinase inhibitor (LY294002) is shown in figure 4.2. Renal 
sympatho-activation induced by resistin was prevented by pre-treatment with LY294002 
(Fig 4.2). The changes in renal SNA were significantly different between the groups 
(F(1,120) = 7.902, P<0.05) (Fig 4.3).  
 
The effect of LY294002 alone was not different from vehicle (figure 4.4). Inhibition of 
ERK1/2 by U1026 did not attenuate the excitatory effect on RSNA induced by resistin (Fig 
4.4).  
69  
RSNA
IRSNA
Pre Resistin  (+ LY294002)       Post Resistin (+ LY294002)
RSNA
IRSNA
Pre Resistin                                 Post Resistin
 
Figure 4.2 
Screen capture of raw recordings of renal sympathetic nerve activity (RSNA) and integrated 
renal SNA (IRSNA) before and after resistin (7µg) in the presence of the PI 3-Kinase 
inhibitor, LY294002 (5µg) administered into the lateral brain ventricle. ∟, horizontal bar =2 
seconds, vertical bar =200mV (RSNA) and 10mV.s (IRSNA).   
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Figure 4.3 
 The percent changes in renal sympathetic nerve activity (RSNA) from basal levels over time 
following the administration of resistin (7µg) in the presence of LY294002 (5µg, n=5) or 
vehicle (DMSO; n=7). *p<0.05 
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Figure 4.4 
The percent change in renal sympathetic nerve activity (RSNA) from basal levels 3h post 
injection of vehicle (n=5), LY294002 (5µg, n=3), resistin (7µg, n=7) alone, and resistin 
(7µg) in the presence of U0126 (7µg, n=3). *p<0.05 compared to the vehicle group. 
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4.4 Discussion 
The main finding in the present study showed that resistin increased the renal SNA via PI 3-
Kinase but not through ERK1/2. Pre-treatment with the PI 3-Kinase inhibitor (LY294002) 
prevented the renal sympatho-excitatory action of resistin. Leptin, too, increases renal SNA 
via the PI 3-Kinase signalling pathway (63, 139), suggesting both adipokines act through 
similar mechanisms to elicit renal sympatho-excitation. Presumably, this means that there is 
a common nucleus in the brain mediating the increased renal SNA, but this key common site 
is not yet identified.  
 
Since we used intracerebroventricular injections, it is important to note that the site of action 
of inhibition of PI 3-Kinase may be different from that at which the adipokines directly act. 
To investigate this possibility will require direct microinjections into specific nuclei in the 
brain. The central sites directly activated by resistin are not yet clearly elucidated. Studies 
using the protein Fos as a marker of increased neuronal activity, suggest the paraventricular 
nucleus is a potential site of action of resistin (43, 131, 133). Furthermore, it is known that 
stimulation of neurons in the paraventricular nucleus results in increased renal SNA (140). 
Thus, since studies show that resistin activates neurons in the paraventricular nucleus and 
increases renal SNA, the results suggest the paraventricular nucleus may be important in 
mediating the action of resistin on renal SNA. This, however, requires confirmation. The 
effect of resistin on renal SNA observed in this experiment did not involve ERK1/2, since 
inhibition of ERK1/2 by U1026 did not attenuate the excitatory effect on renal SNA induced 
by resistin. This effect is similar to leptin, further supporting similar pathways are utilised by 
resistin and leptin to increase renal SNA. 
 
73  
In-vitro studies and cell based assays have shown that U0126, the ERK1/2 inhibitor used in 
this study, specifically blocks ERK pathways and LY294002 is one of the most specific 
inhibitors of PI 3-Kinase. It does, however, also inhibit Casein Kinase 2 signalling pathways 
in-vitro (141). Whether this occurs in-vivo has not been investigated. Nonetheless, this PI 3-
Kinase inhibitor (LY294002) is commonly used in in-vivo experiments (127, 138, 139). 
Data from studies investigating PI 3-Kinase role on renal sympatho-excitation induced by 
leptin, together with the present in-vivo work suggest that PI 3-Kinase mediates resistin 
effect on renal SNA. The current work also clearly shows that ERK1/2 is not involved in the 
action of resistin on renal SNA. 
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Chapter 5: Effects of resistin on sympathetic nerve 
activity to brown adipose tissue and thermogenesis. 
5.1 Introduction 
Obesity is a complex condition in which there may be metabolic dysfunction and an 
imbalance between energy intake and expenditure.  Brown adipose tissue (BAT) is important 
in thermogenesis and energy expenditure in animals and in neonates and recent studies have 
now highlighted considerable functional deposits of BAT in adult humans (119, 142).  The 
activity of brown adipose tissue can be dramatically influenced by alterations in sympathetic 
nerve activity to brown adipose tissue(118). 
 
The adipokine, leptin, is known to increase energy expenditure and stimulate thermogenesis 
in BAT by increasing BAT SNA (63). Leptin also reduces fat tissue mass and lipid 
accumulation, preventing the development of obesity (121). Resistin also, has important 
effects on energy metabolism (143). Similar to leptin, resistin reduces energy intake by 
reducing food intake and the expression of key neurotransmitters in the hypothalamus 
involved in central dietary pathways (117), however, the role of resistin on energy 
expenditure via thermogenesis in BAT is not known. 
 
The aims of the present study were to determine the acute effects of resistin on 
thermogenesis in BAT, thus I investigated the effects of ICV administration of resistin on 
BAT temperature, body core temperature and sympathetic nerve activity to the BAT.
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5.2 Methods 
5.2.1 Experimental protocols 
Rats were fasted overnight before the experiment. On the day of the experiment, anesthesia 
was induced using isoflurane gas (2.5–3%) in O2. The femoral vein was cannulated to enable 
infusion of the drugs and to maintain anesthesia (iv urethane 1–1.4 g/kg initially, followed 
by supplemental doses of 0.05 g/kg as required). The femoral artery was cannulated to allow 
the measurement of arterial pressure. Mean arterial pressure and heart rate were calculated as 
explained in details in the Chapter 2 (Section 2.2). 
 
Intracerebroventricular administration: In one series of experiments the mean arterial 
pressure, heart rate, body core temperature and BAT temperature were recorded. In these 
experiments the animals were placed on a constant temperature heating pad but no attempt 
was made to maintain body core temperature. In a separate series of experiments mean 
arterial pressure, heart rate, body core temperature and BAT SNA were measured. In these 
experiments the animals were placed on a heating pad and the body core temperature was 
maintained constant by altering the temperature of the heating pad.  At normal body core 
temperature, BAT SNA is virtually non-existent. In the present work, the resting body core 
temperature was lowered to approximately 35ºC where it was maintained. At this body core 
temperature, resting BAT SNA was clearly observable.  
 
Intravenous administration: In three urethane-anaesthetized rats, resistin (7µg in 7µl) was 
administered intravenously via a femoral vein. BAT temperature and body core temperature 
were recorded for four hours. 
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In all experiments, resting levels were recorded for at least 10 min prior to the injection of 
resistin (7µg, n=3 to 8 per group), or vehicle (artificial cerebrospinal fluid, n=4 to 8 per 
group). Following the injections, all variables were monitored continuously and recorded 
every 15 minutes over the next 4 hours. 
 
5.2.2 Statistical analysis  
The resting levels of body core temperature and BAT temperature prior to the injections 
were compared between the resistin treated and vehicle injected (control) groups using 
Student’s unpaired t-test.  The integrated SNA was calculated over a period of 1-2 minutes at 
each time point and expressed as a percentage of the resting level prior to the injections. 
Changes in body core temperature, BAT temperature, and BAT SNA were compared 
between groups in each experimental series by using two-way ANOVA with repeated 
measures. All results are expressed as means ± SE. P<0.05 was considered to be statistically 
significant.  
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5.3 RESULTS 
5.3.1 Effects of resistin on BAT temperature and body core temperature  
Resting BAT temperatures prior to ICV resistin or vehicle treatments were not significantly 
different between the two groups. Similarly resting body core temperatures prior to resistin 
or vehicle were not significantly different (Fig 5.1).  
 
ICV administration of resistin induced a marked reduction in BAT temperature (1.27 + 0.46 
ºC) and this was significantly different from the vehicle-treated group (Fig 5.1). The ICV 
administration of resistin also elicited a gradual steady fall in body core temperature (1.32 + 
0.49 ºC). This was not observed in the vehicle-treated group (Fig 5.1), although the 
difference between the groups, did not attain statistical significance. 
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Figure 5.1 
Temperature in brown adipose tissue (Tbat) and the body core temperature (Tcore) prior to 
intracerebroventricular administration of resistin (7µg; n=8) or control (artificial CSF; n=8, 
n=6 for Tcore) are shown in the bar graphs.  The changes in Tbat and Tcore from resting 
levels over four hours following administration of resistin or artificial CSF (control) are 
shown in the right panels.  *p<0.05; F(1,224) = 5.815, resistin vs control. 
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5.3.2 Effects of intravenous resistin  
To determine whether leakage of resistin from the cerebral ventricles into the systemic 
circulation could account for the changes described, we injected resistin intravenously at the 
same dose (7ug) as that administered ICV.  Intravenous resistin did not significantly change 
BAT temperature or body core temperature compared to resting levels recorded prior to 
resistin (Fig 5.2). 
 
 
5.3.3 Effects of resistin on BAT SNA 
Original recordings of BAT SNA from animals treated with ICV resistin or vehicle are 
shown in figure 5.3.  ICV resistin reduced BAT SNA by over 50%.  This occurred within 2 
hours of the injection of resistin and BAT SNA remained reduced for the duration of the 
observation (Fig 5.4). This response was significantly different from the vehicle-treated 
group in which BAT SNA was slightly elevated over time (Fig 5.4).  In these experiments 
the body core temperature was carefully maintained constant.  
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Figure 5.2 
Average brown adipose tissue (BAT) temperature and body core temperature pre and at 4 
hours post intravenous resistin (7ug, n=3).  
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Figure 5.3 
Screen capture of the raw recordings of brown adipose tissue sympathetic nerve activity 
(BAT SNA) and integrated BAT SNA (IBAT SNA) before and after resistin (7µg) or vehicle 
(artificial CSF) administered into the lateral brain ventricle. ∟, horizontal bar =2.5 seconds, 
vertical bar =100mV (BAT SNA) and 25mV.s (IBAT SNA).  
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Figure 5.4 
The percent changes in brown adipose tissue sympathetic nerve activity (BAT SNA) from 
resting levels over four hours following intracerebroventricular administration of resistin 
(7µg; n=5) or control (artificial CSF; n=4). *P<0.05; F(1,112) = 6.211, resistin vs control.  
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5.4 Discussion 
The present study is the first to directly measure the effects of resistin administration on 
thermogenesis in BAT.  The key findings of the study show that intracerebroventricular 
resistin reduced brown adipose tissue sympathetic nerve activity. As a likely consequence of 
that effect, the temperature of brown adipose tissue decreased and there was a decrease in 
body core temperature.  
 
We found that ICV resistin administration induced a significant decrease of over 50% in 
BAT SNA.  This indicates that resistin reduces thermogenesis and this is supported by our 
finding, in separate animals, of a reduction in BAT temperature and a concomitant decrease 
in body core temperature.  The ability of resistin to act centrally to reduce thermogenesis 
contrasts with the actions of leptin which increases BAT SNA (62, 63), an action mediated 
via the hypothalamic arcuate nucleus (63).  Thus, leptin’s actions of reducing food intake 
and increasing thermogenesis result in an increased energy output and resultant weight loss.  
By contrast, it appears that resistin can decrease food intake and thermogenesis, thus 
counteracting the reduced dietary intake with mechanisms designed for the preservation of 
energy.  This could contribute to the lack of effect on body weight reported following 
resistin administration (43, 47). 
 
There has been considerable discussion lately about the role of thermogenesis and BAT in 
metabolic regulation in humans. Until recently, brown adipose tissue was believed to be 
present only in infants, however, it is now recognized that brown adipose tissue is present 
and is metabolically active in adults (119).  Stimulation of thermogenesis in BAT may have 
dramatic effects on energy expenditure since calculations show that activation of 40-50 g of 
BAT in humans could result in a 20% increase in energy expenditure (120).  This could have 
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dramatic effects on weight loss. Thus, antagonists to resistin may elicit increases in BAT 
SNA which could be an efficient therapeutic mechanism to reduce body weight.  
 
The effects observed following ICV resistin were centrally mediated since intravenous 
administration of the same dose of resistin did not have marked effects on BAT or body core 
temperature.  In chapter 3 of this thesis, it was shown that ICV resistin administration 
increases the number of Fos positive cell nuclei in the hypothalamic paraventricular, 
supraoptic and subfornical nuclei, but there was no significant increase in the arcuate nucleus 
(133). Our data are consistent with the findings that activation of the paraventricular nucleus 
inhibits BAT SNA (144) since we found that resistin increased activation in neurons in 
paraventricular nucleus and inhibited BAT SNA.  
 
In conclusion, the present findings in addition to the findings reported in previous chapters 
indicate that acute administration of resistin has differential effects on sympathetic nerve 
activity to tissues involved in metabolic and cardiovascular regulation. The decreased BAT 
SNA and the increased lumbar and renal SNA elicited by resistin may contribute to the 
metabolic and cardiovascular dysfunction observed in obesity and diabetes. 
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Chapter 6: Intracellular mechanism mediating the effects 
of resistin on brown adipose tissue thermogenesis 
6.1 Introduction 
Resistin can act centrally to influence energy balance. It reduces food intake and the 
expression of key neurotransmitters in the hypothalamus involved in central dietary 
pathways (117).  In chapter 5, it was shown that resistin reduced brown adipose tissue (BAT) 
and body core temperatures and sympathetic nerve activity (SNA) to BAT, resulting in 
reduced thermogenesis in BAT and reduced energy expenditure (133).  BAT is an important 
organ for thermogenesis and energy expenditure in animals and in neonates and recent 
studies have now highlighted considerable functional deposits of brown adipose tissue in 
adult humans (119, 142). 
 
BAT function is tightly regulated by the sympathetic nervous system through activation of 
adrenoreceptors that ultimately activate UCP1 and other important thermogenic genes. The 
transcriptional co-activator peroxisome proliferator-activated receptor gamma coactivator 1-
α (PGC-1α) is abundantly expressed in BAT and can also activate many aspects of the 
adaptive thermogenic program (145). In this regard, PGC-1α has been shown to increase the 
transcriptional activity of several prominent nuclear ligand-binding receptors that can 
collectively stimulate mitochondrial biogenesis (146). 
 
Recently I have shown that resistin reduces thermogenesis in BAT by decreasing the 
sympathetic nerve activity to BAT and reducing BAT temperature and body core 
temperature (133, 147), however, the intracellular signalling pathways mediating resistin’s 
actions on sympathetic nerve activity to BAT are not known. Phosphatidylinositol 3-kinases 
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(PI 3-Kinase) and extracellular regulated kinases (ERK) 1/2 are known to mediate the 
actions of resistin on different cellular migration, hypertrophy and proliferation (82, 136, 
137). PI 3-Kinase and ERK1/2 within the brain are known to be involved in sympathetic 
nerve activity responses, as shown by the critical role of PI 3-Kinase in mediating the 
changes in renal sympathetic nerve activity induced by central administration of leptin (139, 
147) and resistin (139, 147), and in the lumbar sympathetic nerve activity changes induced 
by insulin (138).  ERK1/2 activation mediates the changes induced by leptin and insulin, on 
sympathetic nerve activity to brown adipose tissue (63, 138).  
 
In the present study, the role of PI 3-Kinase and ERK1/2 in the brain in mediating the effects 
of resistin on BAT SNA, was investigated. Based on the findings, I further explored the role 
of ERK1/2 in the brain in mediating the reduction in BAT temperature induced by centrally 
administered resistin and on the changes in the expression of UCP1 and PGC-1α, genetic 
markers of BAT thermogenesis.  
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6.2 Methods 
6.2.1 Experimental protocols 
Rats were fasted overnight before the experiment. On the day of the experiment, anesthesia 
was induced using isoflurane gas (2.5–3%) in O2. The femoral vein was cannulated to enable 
infusion of the drugs and to maintain anesthesia (iv urethane 1–1.4 g/kg initially, followed 
by supplemental doses of 0.05 g/kg as required). The femoral artery was cannulated to allow 
monitoring of arterial pressure as explained in detail in Chapter 2 (Section 2.2). 
 
Recording of BAT SNA 
In these experiments the animals were placed on a heating pad and the body core 
temperature was maintained constant by altering the temperature of the heating pad.  At 
normal body core temperature, BAT SNA is virtually non-existent. In the present work the 
resting body core temperature was lowered to approximately 35ºC where it was maintained. 
At this body core temperature, resting BAT SNA was clearly observable.  
 
In these experiments, resting levels were recorded for at least 10 min prior to the ICV 
injections. The PI 3-Kinase inhibitor (LY294002, 5 µg in 2µl of DMSO) or the ERK1/2 
inhibitor (U0126, 7µg in 2µl of DMSO) was administered ICV followed 15 minutes later by 
resistin (7µg in 7µl) or vehicle (artificial cerebrospinal fluid 7µl) and the responses were 
monitored continuously and recorded every 15 minutes for 3 hours.  
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Recording of body core temperature and BAT temperature 
In a separate series of experiments body core temperature and BAT temperature were 
recorded in anaesthetised rats. In these experiments the animals were placed on a constant 
temperature heating pad but no attempt was made to maintain body core temperature. In 
these experiments, resting levels of BAT temperature and body core temperature were 
recorded for at least 10 minutes prior to the ICV injections. The changes in temperature were 
monitored for 3-4 hours after ICV resistin in rats pre-treated with the ERK1/2 inhibitor, 
U0126 (7 µg in 2 µl, n=5) (administered 20-30 minutes earlier) or vehicle (DMSO, n=8). In 
separate groups, vehicle (n=7) or U0126 (n=5) were administered alone. 
BAT sampling and processing 
3-4 hours after the ICV injections, animals were euthanized; BAT was rapidly excised, 
frozen in liquid nitrogen, and stored at -80°C for subsequent RNA extraction. Samples were 
processed for PCR experiments as explained in detail in Chapter 2 (Section 2.4). Due to 
technical problems, mRNA levels could not be measured in BAT from all animals. 
 
6.3 Results 
6.3.1 Role of ERK1/2 signalling pathway in mediating the action of resistin on BAT 
SNA 
Original recordings of the BAT SNA from representative animals treated with ICV resistin 
in the presence or absence of the ERK1/2 inhibitor (U0126) are shown in figure 6.1. Resistin 
significantly reduced BAT SNA which reached a maximum reduction within about 120 
minutes and then remained at that plateau level for the duration of the observation period 
(Fig 6.1).  
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Pre-treatment with U0126 prevented the inhibitory action of resistin on BAT SNA for the 
first 150 minutes. Thereafter however, BAT SNA fell to levels seen in the group 
administered resistin in the absence of U0126 (Fig 6.1). U0126 alone had no significant 
effect on BAT SNA (Fig 6.2). The reduction in BAT SNA induced by resistin was not 
prevented by inhibition of PI 3-Kinsae using LY294002 at any time during the observation 
period (Fig 6.2). 
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Figure 6.1 See the next page for figure legends 
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Figure 6.1 
(A)  Screen capture of raw recordings of brown adipose tissue sympathetic nerve activity 
(BAT SNA) and integrated BAT SNA (IBAT SNA) before, 2 hours and 4 hours after resistin 
(7µg) in the presence of vehicle (Panel A) or ERK1/2 inhibitor (U0126, 7µg) (panel B) 
administered into the lateral brain ventricle. ∟, horizontal bar =2 seconds, vertical bar 
=200mV (BAT SNA) and 10mV.s (IBAT SNA).   
 
(B)  The percent changes in BAT sympathetic nerve activity (BSNA) from baseline levels 
over time following administration of resistin (7µg) in the presence or absence of U0126 
(7µg, n=4). 
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Figure 6.2 
(C) The percent change in BAT sympathetic nerve activity (BSNA) from basal levels 4h 
post injection of vehicle (n=4), U0126 (7µg, n=5), resistin (7µg, n=5) alone, and resistin 
(7µg) in the presence of LY294002 (5µg, n=3). *p<0.05 compared to the vehicle group. 
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6.3.2 BAT temperature and body core temperature and effects of ERK1/2 inhibition  
Resting levels of BAT and body core temperatures before ICV injection of the drugs are 
shown in Figure 6.3. Compared with the control group, there was a small but statistically 
significant difference in resting BAT temperature in groups that received resistin. Resting 
body core temperatures before ICV injection of resistin were not different between the 
groups (Fig 6.3).  
 
ICV injection of resistin markedly reduced both BAT temperature (P < 0.005) and body core 
temperatures (Fig 6.3). In rats pre-treated with the ERK1/2 inhibitor, U0126, resistin’s effect 
on BAT temperature was significantly attenuated by over 60% (P < 0.05) (Fig 6.3). U0126 
alone did not significantly change BAT temperature (Fig 6.3). Resistin decreased body core 
temperature by 1.09 + 0.44 ºC from resting levels, and although U0126 attenuated this effect 
by over 60%, the change was not statistically significant (Fig 6.3). 
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Figure 6.3 
Bar graph shows brown adipose tissue temperature (Tbat) and body core temperature (Tcore) 
before intracerebroventricular administration of (i) resistin alone (7 µg, n=7 for Tbat, n=8 for 
Tcore), (ii) resistin in the presence of U0126 (7 µg in 2 µL, n=5), (iii) U0126 alone (n=6) or 
(iv) vehicle (Control, n=8). In the right panels, changes in Tbat and Tcore from resting levels 
over time in response to treatments are shown. *p < 0.05: resistin alone vs resistin in the 
presence of U0126. **p< 0.005, resistin alone vs control. 
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6.3.3 Effects of resistin on UCP1 and PGC-1α mRNA expression 
UCP1 mRNA expression was lower in the resistin-treated group (0.11+0.01) than in the 
control group (1.24+0.85), but this difference was not statistically significant. Inhibiting 
ERK1/2 in the brain blunted resistin’s effect on UCP1 expression, however, this effect was 
not statistically significant (Fig 6.4A).  Figure 6.4B shows the levels of mRNA expression 
for PGC-1α in BAT. There were no statistically significant differences in PGC-1α 
expression between groups. 
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Figure 6.4 See the next page for figure legends 
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Figure 6.4  
(A) UCP1 and (B) PGC-1α mRNA abundance in brown adipose tissue from control (n= 4 
for UCP1, n=6 for PGC-1α), resistin (n=5), U0126 (ERK1/2 inhibitor) + resistin (n=4) and 
U0126 (n=3) groups. Values are expressed relative to 18S ribosomal RNA and presented in 
arbitrary units (mean ± SEM).  
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6.4 DISCUSSION 
The present study is the first to report on (i) the effects of central ERK1/2 inhibition in the 
brain on thermogenesis induced by central resistin and (ii) the effects of resistin on genetic 
markers of thermogenesis in BAT. The findings show that ERK1/2 in the brain is involved 
in the action of resistin on thermogenesis in BAT.  
 
Metabolic conditions like obesity are characterised by an imbalance between energy intake 
and expenditure. One mechanism to increase energy expenditure is to increase 
thermogenesis in BAT and is well recognised in rodents. There is considerable BAT in 
human newborns which plays an important role in temperature regulation and non-shivering 
thermogenesis and recent work has now identified considerable functional BAT deposits in 
adult humans suggesting an important role in energy expenditure in adults (142).  The 
mechanism involved in the inhibition of BAT SNA by resistin was investigated in the 
present study.  I found that blocking ERK1/2 prevented the inhibitory action of resistin on 
BAT SNA for approximately 150 minutes. To account for this finding, it is possible that the 
effect of U0126 either wore off after that time and this is consistent with the findings of 
previous work that showed the half-life of U0126 injected into the brains of finches was 
about 2 hours (148). Alternatively, other intracellular mechanisms may contribute to the 
actions of resistin on BAT SNA. In rats, in which ERK1/2 inhibition prevented the response 
induced by leptin and insulin on BAT SNA (63, 138), the duration of action of U1026 was at 
least 6 hours, supporting the idea of alternative mechanisms. The mechanism by which 
ERK1/2 can mediate the reduction in BAT SNA induced by resistin and the opposing 
increase induced by leptin is unclear.  It is likely, however, that different cell groups mediate 
the actions of the two adipokines on BAT SNA.  
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The attenuation of the resistin response by inhibition of ERK1/2 on BAT SNA observed in 
this study was selective, since inhibition of PI 3-Kinase did not affect the inhibitory action of 
resistin on BAT SNA. Furthermore, inhibition of ERK1/2 did not affect the sympatho-
excitatory action of resistin on renal nerve activity, suggesting that the dose of U0126 used 
in this study to block ERK1/2 pathways in the brain, did not act non-specifically to influence 
SNA. 
 
 
In the present study, acute ICV injections of resistin markedly decreased BAT temperature, 
and this effect was significantly attenuated when central ERK1/2 was inhibited. The fall in 
BAT temperature was most likely responsible for the resistin-induced decrease in body core 
temperature. When central ERK1/2 was inhibited, the decrease in body core temperature 
induced by resistin was blunted (in excess of 60%) but the effect was not statistically 
significant, probably due to the greater variance seen in the control group. Nonetheless, the 
present results are in agreement with my earlier finding, showing that central resistin reduces 
BAT SNA (Chapter 4), and that the effect was mediated by central ERK1/2 (Present work).  
 
In this study, central resistin treatment reduced UCP1 mRNA expression in BAT, which is 
consistent with the findings that resistin reduces BAT temperature and BAT SNA. The 
present data suggests this response is blunted when central ERK1/2 signalling pathways are 
inhibited, however, due to the variability in UCP1 expression in the control group and the 
limited sample size, these changes were not statistically significant. UCP1 is present on the 
inner mitochondrial membranes of adipocytes in BAT. It is responsible for uncoupling ATP 
production from oxidative phosphorylation, by reducing the proton gradient, which 
generates heat (118). This is important for non-shivering thermogenesis and maintaining 
normal body temperature. It is also believed UCP1 may play a vital role in managing body 
weight through its ability to expend energy. Indeed, Feldmann and colleagues recently 
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demonstrated UCP1 ablation induced obesity in mice fed a control diet under thermoneutral 
conditions (149). To our knowledge, no other study has investigated the effects of centrally 
administered resistin on UCP1 expression in BAT. The resistin-induced UCP1 reduction 
observed in this study is consistent with reduced thermogenic capacity and energy 
expenditure.  
 
PGC-1α belongs to a family of nuclear transcriptional cofactors that regulate mitochondrial 
biogenesis and are involved in the regulation of brown adipocyte-specific genes (146). PGC-
1α putatively controls UCP1 expression although this role remains controversial since 
studies have shown that PGC-1α and UCP1 gene expression in brown adipocytes are not 
necessarily correlated (150, 151). In the current study, the average PGC-1α mRNA 
abundance was lower in the resistin treated group, however, it did not reach statistical 
significance. Nonetheless, it is noteworthy that PGC-1α did follow the same expression 
pattern between groups as UCP1.  
 
In conclusion, the main finding of this study highlights the role of ERK1/2 signalling 
pathways in the brain in mediating the action of resistin on thermogenesis in BAT. 
Moreover, centrally administered resistin decreased the expression of UCP1, which is in 
agreement with the finding.  
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Chapter 7: General discussion and conclusion 
This study showed for the first time that the adipokine resistin acts centrally to influence 
sympathetic nerve activity (SNA). Prior to this study, leptin and adiponectin were the only 
adipokines known to influence the SNA. In the present work, I found that centrally 
administered resistin increased lumbar and renal SNA and reduced brown adipose tissue 
(BAT) SNA. Therefore resistin has a non-generalised effect on SNA. It is not uncommon to 
observe differential responses in SNA. An increase in sympathetic drive to the 
cardiovascular tissues could contribute to increased vascular resistance. A reduction in BAT 
SNA induces a reduction in thermogenesis and reduced energy expenditure. Such actions 
could contribute to the undesirable cardiovascular and metabolic abnormalities characteristic 
of metabolic syndrome, obesity and diabetes. 
 
Increased SNA to the kidney and muscle vasculature is observed in obesity, indeed, the level 
of sympathetic nerve activity to the skeletal muscle vasculature in obese individuals is 
correlated to abdominal visceral adiposity (60). The findings of this thesis show that resistin 
increases renal and lumbar SNA, suggesting that resistin could contribute to the SNA 
disturbances observed in obesity, but this needs to be investigated in future studies. In 
hypertension, SNA is elevated (3, 56, 152, 153), however, we did not observe any significant 
increase in blood pressure following the acute administration of resistin. The effects of long-
term central resistin administration on blood pressure, however, have yet to be studied.  
Nonetheless, in obesity, both resistin and leptin are elevated, thus the possibility exists that 
these two adipokines may act synergistically to increase renal and lumbar SNA. Since 
increased renal SNA can induce sodium retention and alter renal haemodynamics, and 
thereby influence long term blood pressure regulation, the two adipokines may act in concert 
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to contribute to obesity-induced hypertension. Further studies in animal models of obesity 
are needed to explore this suggestion. 
 
The other major finding of this work was that centrally administered resistin reduced 
thermogenesis in BAT. The present work is the first to directly measure BAT SNA 
following administration of resistin. I found there was a significant decrease of over 50% in 
BAT SNA following resistin administration.  This indicates that resistin reduces 
thermogenesis and this is supported by the finding, in separate animals, of a reduction in 
BAT temperature and a concomitant decrease in body core temperature.  The ability of 
resistin to act centrally to reduce thermogenesis contrasts with the actions of leptin which 
increases BAT SNA (62, 63), an action mediated via the hypothalamic arcuate nucleus (63). 
Thus, leptin’s actions of reducing food intake and increasing thermogenesis result in an 
increased energy output and resultant weight loss.  By contrast, resistin can decrease 
thermogenesis as well as food intake. Thus, the reduced dietary intake is counteracted with 
mechanisms designed for the preservation of energy. 
 
 
Consistent with the finding that resistin reduces thermogenesis in BAT, in the present study, 
I also found that central resistin treatment reduced the expression of uncoupling protein-1 
(UCP1) mRNA, a genetic marker of thermogenesis in BAT. UCP1 is positioned on the inner 
mitochondrial membrane of brown adipocytes and is responsible for uncoupling the 
production of ATP from oxidative phosphorylation, thereby  generating heat (118). While 
maintaining normal body temperature, it is also postulated UCP1 may play a vital role in 
body weight management through its ability to expend energy. Indeed, Feldmann and 
colleagues recently demonstrated UCP1 ablation to induce obesity in mice feed control diets 
under thermoneutral conditions (149).  The reductions in UCP1 abundance observed in the 
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current study in response to resistin treatment indicate a reduction in thermogenic capacity 
and subsequent potential for energy expenditure. Such actions could contribute to metabolic 
dysfunctions characteristic of disease states such as obesity and diabetes. 
 
Prior to this work, the intracellular signalling pathways mediating resistin’s actions on 
sympathetic nerve activity were not known. It was known that phosphatidylinositol 3-
kinases (PI 3-Kinase) and extracellular regulated kinases (ERK) 1/2 were involved in the 
actions of resistin on cell growth, differentiation, metabolism and intracellular trafficking. PI 
3-Kinase and ERK 1/2 are involved in sympathetic nerve activity responses as shown by the 
critical role of PI 3-Kinase in mediating the changes in renal sympathetic nerve activity 
induced by central administration of leptin (139), and the lumbar sympathetic nerve activity 
changes induced by insulin (138).  ERK1/2 activation mediates the changes induced by 
leptin, and insulin, on sympathetic nerve activity to brown adipose tissue (63, 138).  
 
In the present work, it was demonstrated that PI 3-Kinase but not ERK1/2 mediated the 
sympatho-excitatory action of resistin on renal SNA. Leptin, too, increases renal SNA via 
the PI 3-Kinase signalling pathway (63, 139), suggesting both adipokines act through similar 
mechanisms to elicit renal sympatho-excitation. Presumably, this means that there may be a 
common nucleus in the brain mediating the increased renal SNA, but this key common site 
is not yet identified. Since we used intracerebroventricular injections, it is important to note 
that the site of action of inhibition of PI 3-Kinase may be different from that at which the 
adipokines directly act. The central sites directly activated by resistin are not yet clearly 
identified. Studies including the present work, using the protein, Fos, as a marker of 
increased neuronal activity, suggest the paraventricular nucleus as a potential site (43, 131, 
133). 
 
104  
The mechanism involved in the inhibition of BAT SNA by resistin was also investigated in 
the present work. I found that ERK1/2 pathway but not PI 3-Kinase was involved in the 
action of resistin on BAT SNA. This was confirmed by finding that acute 
intracerebroventricular administration of resistin induced a marked decrease in BAT and 
body core temperature but this was attenuated by central inhibition of ERK1/2. Moreover, 
resistin was shown to reduce UCP1 expression which is a marker of thermogenesis in BAT. 
A trend suggesting attenuation of this response was observed by inhibition of ERK1/2, 
which further highlights the role of ERK1/2 in mediating the effects of central resistin on 
thermogenesis in BAT. 
 
ERK1/2 is also known to mediate the action of central leptin on increasing thermogenesis in 
BAT. The mechanism by which ERK1/2 can mediate the reduction in BAT SNA induced by 
resistin and the opposing increase induced by leptin is unclear.  It is likely, however, that 
different cell groups mediate the actions of the two adipokines on BAT SNA.  
 
In conclusion, this study showed that in contrast to renal and lumbar SNA, resistin and leptin 
have opposing actions on the activity of sympathetic nerves innervating BAT. Taken 
together, the results suggest that the two adipokines have opposing actions on thermogenesis 
but similar actions on sympathetic nerves innervating cardiovascular organs.  This suggests 
that in conditions in which plasma levels of both adipokines are elevated, for example 
obesity, the two could interact to contribute to the cardiovascular and metabolic disturbances 
that are observed in those metabolic conditions.  
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